

Cancer incidence and mortality in Western Australia, 2006

A report of the Western Australian Cancer Registry

**Data Collection and Analysis, Information Management and Reporting
Department of Health
Perth, Western Australia**

December 2007

Statistical Series Number 82

ISSN: 0816-2999

© 2007 Information Management and Reporting, Department of Health, Western Australia

Material in this publication may be reproduced and used, with acknowledgment, for genuine educational and health research purposes; no part may be published elsewhere nor copied and stored in any electronic retrieval system without the consent of the copyright holders.

Contact regarding enquiries, additional information and further copies:

Principal Medical Officer/Manager
Western Australian Cancer Registry
Department of Health
1st Floor, C Block
189 Royal St
East Perth WA 6004
AUSTRALIA

Fax : +61 (0)8 9222 4236

Phone: +61 (0)8 9222 4022

E-mail - wacanreg@health.wa.gov.au

(No "spam" or commercial offers; cancer-related enquiries only please.)

Internet - Department of Health home page

www.health.wa.gov.au

- Western Australian Cancer Registry home page -

www.health.wa.gov.au/wacr/

Cancer Registry Staff, 2004-2007

Timothy Threlfall	Principal medical officer/ Manager	John Langley	Analyst/programmer
Judith Thompson	Medical officer/ coding advisor	Cathy Johnston Colleen Kontor	Data quality officer Data quality officer
Kaye Garrod	Senior Data quality officer	Nola Olsen	Research officer
Charmaine Brewster	Data quality officer	Bev Jamieson	Clerical Officer

Cancer Registry Scientific Advisory Committee, 2001-2007

Dr Michael Byrne	Oncologist	Dr Christobel Saunders	Surgeon
Dr James Semmens	Epidemiologist	Dr Yee Leung	Gynaecologic oncologist
Dr Peter Heenan	Pathologist	Dr Gordon Harloe	Pathologist
Dr Cecily Metcalf	Pathologist	Dr Judith Thompson	Cancer Registry
Dr Chris Harper	Radiation Oncologist	Dr Timothy Threlfall	Cancer Registry

Citation

The following citation is suggested in referring to this report:

Threlfall TJ, Thompson JR (2007). *Cancer incidence and mortality in Western Australia, 2006*. Department of Health, Western Australia, Perth. Statistical Series Number 82.

Contents

Contents	Page
List of Tables	i
List of Figures	i
Acknowledgments	ii
Summary	iii
1 Overview and Methods	1
1.1 Overview of this report	1
1.2 General structure; how to find information	1
1.3 Interpretation of changes and differences	1
1.4 Statistical methods	2
2 Cancer in Western Australia, 2006	3
2.1 All cancers	3
2.1.1 Incidence	3
2.1.2 Mortality	4
2.1.3 Mortality to incidence ratios	5
2.2 Common cancers	5
2.2.1 Incidence	5
2.2.2 Mortality	6
2.3 Cancer in different age groups	8
2.3.1 Cancer in children	8
2.3.2 Cancer in the 15-39 years age range	9
2.3.3 Cancer in the 40-64 years age range	10
2.3.4 Cancer in persons aged 65 and over	11
3 Cancer in Western Australia: special topics	14
3.1 Death Certificate Only cancers	14
4 References	15
List of Appendices	16

List of tables

	Page
1. Cancer incidence and mortality, WA, 2006: leading types in males and females	7
2. Cancer incidence, WA, 2006: leading types by sex and age group	12
3. Cancer mortality, WA, 2006: leading types by sex and age group	13

List of figures

	Page
1. Age-specific all-cancers incidence and mortality rates, WA, 2006.	3
2. Cancer incidence, WA, 2006: common cancers	5
3. Cancer mortality, WA, 2006: common cancers	6
4. Cancer in children under 15 years of age, WA, 2006: most common types.	8
5. Cancer incidence, WA, 2006: common cancers in the 15 to 39 years age group	9
6. Cancer mortality, WA, 2006: common cancers in the 15 to 39 years age group	9
7. Cancer incidence, WA, 2006: common cancers in the 40 to 64 years age group	10
8. Cancer mortality, WA, 2006: common cancers in the 40 to 64 years age group	10

List of figures (cont.)

	Page
9. Cancer incidence, WA, 2006: common cancers in the 65 years & over age group	11
10. Cancer mortality, WA, 2006: common cancers in the 65 years & over age group	11
11. Death Certificate Only (DCO) cancers, 2006: common types	14
12. "DC & HMDS" cancers, 2006: common types	14

Acknowledgments

This report is based on data recorded and maintained by the staff of the Western Australian Cancer Registry, whose dedication and attention to detail are much appreciated.

We also wish to acknowledge the invaluable contribution of the Western Australian pathologists, haematologists and radiation oncologists who supply the vast majority of the Registry's primary notifications, and the health professionals and organisations who supply additional information in response to our enquiries. Members of the Registry's Scientific Advisory Committee have given valuable advice concerning a wide range of issues.

The cooperation of other Australian Cancer Registries regarding procedures, coding, duplication and demarcation issues, and of the National Cancer Statistics Clearing House at AIHW, Canberra, is acknowledged as playing a vital part in ensuring data quality and comparability.

The Registry relies on a variety of supporting services in order to produce reports on cancer; these include population figures and projections, mapping, hospitalisation data, legal advice, computing services and general support and encouragement. Thanks are due to other staff of Epidemiology and Analytical Services who have provided assistance, and to staff of Publications and Marketing for cover production and printing arrangements.

Summary

The Western Australian Cancer Registry has provided population-based cancer data since 1982 for use in the planning of health care services and the support of cancer-related research, at local, national and international levels. Most of this report is concerned with invasive tumours, or “cancers”, using standardised reporting practices as used in other cancer registries in Australia and overseas. This report deals primarily with cancer incidence and cancer-related mortality in Western Australian residents, who comprise approximately 10% of the Australian population. All statistics are based on the ICDO-3 coding system.

New cases of cancer, 2006

There were 9692 new cases of cancer recorded in Western Australians in 2006, 5457 (56%) occurring in males and 4235 in females. Age-standardised incidence rates were 362 per 100,000 males, and 270 per 100,000 females, both slightly higher than in 2005. The estimated lifetime risk of cancer to age 75 years was 1 in 3 for males, and 1 in 4 for females.

Cancer-related deaths

Among Western Australian residents, there were 3570 deaths due to cancer in 2006, 2047 in males and 1523 in females. All-cancers mortality rates for 2006 were 123 deaths per 100,000 males (slightly lower than in 2005) and 82 per 100,000 females (slightly higher). As usual in recent years, the most common causes of cancer-related death in males were lung, colorectal and prostate cancers, while lung, breast and colorectal cancers were the most common in females.

Common cancers

The most common cancers in males in 2006 were prostate cancer, melanoma, colorectal and lung cancers. Lung cancer became relatively less common in 2006 in males. Breast cancer predominated among females, followed by colorectal cancer, melanoma and lung cancer, as in 2005. While small decreases were seen in the rate of breast cancer in females in each of the three years to 2005, there has been an increase in 2006 which warrants further monitoring.

There were 44 children under the age of 15 years diagnosed with cancer in 2006 (ASR 11 per 100,000 in males and in females). Cancer at this age is a rare disease and annual variation in numbers and types is considerable. Lymphomas predominated, followed by leukaemias and tumours of the central nervous system (CNS).

Melanoma of the skin was - as in most years since 1982 - the most common cancer in males in the 15-39 years age range, but breast cancer was most common in young females. In persons over the age of 40 years, prostate and breast cancers, melanoma, colorectal and lung cancers, remain the most common incident cancers.

Based on 2006 data, one in 8 men would be expected to have a diagnosis of prostate cancer before the age of 75, and one in 11 women could be expected to develop breast cancer. One in 107 men could be expected to die from prostate cancer before age 75, and one in 63 women to die from breast cancer. However, considering the types of cancer which occur in both males and females, lung cancer was the most common cause of cancer-related death.

Use of alternative data sources

On the basis of previous investigations, Registry staff investigated 1189 hospital-data only (“HMDS-only”) tumour records for 2006, and confirmed 744 cases, rejected many as invalid for WA cancer incidence, while others could not be resolved. This process has increased the apparent WA cancer incidence records by over 6%, and the results are being used in ongoing examination of the cancer notification process; in particular, supporting current initiatives aimed at making “non-pathological” diagnoses directly notifiable by hospitals, and at ensuring haematological tests such as flow cytometry, become a part of the core notification stream received by the Registry.

1 Overview and Methods

1.1 This Report

Overview of this report

This is the latest in this Registry's series of annual all-cancers incidence and mortality reports, and comprises a summary of Registry activities and topical issues, and details of cancer incidence and mortality for 2006. Sections concerning coding and other Registry practices and statistical methods include relevant material for recent years.

The Western Australian Cancer Registry (WACR) is a population-based cancer registry that was established in 1981. Records are based on notification of cancers from pathologists, haematologists and radiation oncologists, and cancer information from death records. The Registry works to collect and disseminate reliable population-based cancer data to assist in the planning of services and in the prevention and treatment of cancer. The **WA Mesothelioma Register** is a separate database maintained within the WACR and reconciled frequently with "mainstream" WACR data. It incorporates specific information for mesothelioma cases, relating to occupational, residential and asbestos exposure history, and the presumed most significant asbestos exposure.

The WACR acts with the delegated authority of the Executive Director of Public Health with respect to the Health (Notification of Cancer) Regulations 1981. Last amended in 1996, these require the notification of *in situ* neoplasms and all non-melanoma skin cancers other than basal cell and squamous cell carcinomas, and all other invasive malignancies and benign CNS tumours (see Appendix 2E). Further changes are currently being sought in order to maintain the relevance of the Registry's data collection. A Discussion Paper concerning proposed changes can be found on the Registry website at www.health.wa.gov.au/wacr/

1.2 General structure; how to find information

Time constraints, including a major Registry software redevelopment project, have forced the adoption of a shorter format for this year's report. The major statistical sections are based on cancers diagnosed, and deaths due to cancer, in 2006. Data for the more common cancers are presented under headings based on incidence, mortality and age, while data for selected geographic areas are presented in Appendices 3D and 3E. Detailed data for all cancers for 2006 are found in the tables of Appendices 3A and 3B. The layout of those tables follows the coding system summarised in material available at www.health.wa.gov.au/wacr/. Readers seeking detailed information for particular cancers not shown in tables, should contact the Registry for further information.

In particular, note that **Information for Appendices 1 and 2 is not printed in this report**, but is available on the Internet, as produced for the 2005 report, at <http://www.health.wa.gov.au/wacr/datr05.html>

1.3 Interpretation of changes and differences

Western Australia is particularly polarised into metropolitan and rural areas, with huge differences in population density and there are likely to be some statistical biases due to the difficulties of transport and the location of services within the State. Throughout this report, an awareness is needed that assessing the importance of changes in cancer incidence and mortality is complex and depends on the underlying population sizes and their age structures. As in previous years, caution is required in assessing changes on the basis of single rate comparisons.

The Cancer Registry database is dynamic, and data are continually updated in the light of the most recent available information. Accordingly, numbers in this report for earlier years may vary slightly from those in previous publications. Ongoing reconciliation processes result in some Western Australian cases being found to have been diagnosed elsewhere, or in earlier years, and case-counts necessarily rise and fall as new information arrives. Mortality information, in particular, often sheds new light on a person's cancer history.

As a guide, while total cancers for 2005 were quoted at 9151 in our previous report,¹ the total currently recorded for 2005 is 9278, an increase of 1.4%. The corresponding increase for 2004 data was 0.9%. Benefits of more timely analysis and reporting must be weighed against the apparent stability of the data as time passes.

1.4 Statistical methods

Statistics from the Registry commonly fall into one of two major groups: **incidence** is reported for all malignancies except primary squamous cell and basal cell skin cancers (SCC and BCC), and **mortality** for all malignancies and certain other tumours or tumour-like conditions). The usual statistics calculated for both types of report are briefly discussed below; formulae and relevant details are in Appendix 2B.

Rates are calculated separately for males and females, expressed as events (diagnoses or deaths) per 100,000 person-years:

Age-specific rates (ASPR) are based on five-year age groups and are calculated by dividing the numbers of cases by the population of the same sex and age group.

Age-standardised rates (ASR in Tables) are calculated by the direct method, as a summation of weighted age-specific rates. Tables show the 95% confidence interval (c.i.) for ASRs.

When a subset of age groups (e.g. 15-39 years) is considered, the term **age-adjusted rate** is used instead of ASR, as standardisation has considered only some age groups, for both cases and population.

The **World Standard Population 1960**² remains in routine use for ASR calculation, as in most cancer registries worldwide. However in some tables a second ASR and 95% c.i. are shown, using the Australian (2001)³ population standard, labelled "ASR2". These ASRs are usually quite different, and comparisons need to take note of which "standard" is being used.

Cumulative Incidence and Lifetime Risk are closely related. **Cumulative incidence** is an estimate of the proportion of persons, up to a specific age, who have been affected by a particular condition at some time. In Registry reports, this is expressed as a percentage.

Lifetime risk (LR) estimates the probability of having cancer (incidence) or dying of it (mortality), up to a specific age. This is derived from the relevant cumulative incidence figures, and calculated for ages 0 to 74 years (see **Appendix 2B** for formulae).

In this report, LR is expressed as a "1 in *n*" chance of diagnosis or death. As indicated in relevant tables, a "-" is used to indicate a lack of data (no cases), and a "*" to indicate no data for cases under 75 years of age, or a "risk" smaller than 1 in 10,000.

Person years of life lost (PYLL) is an estimate of the number of years of life lost due to specific causes, calculated to age 75 years; an index of premature death (see Appendix 2B).

Rates and risks: It should be noted that incidence and mortality **rates** and lifetime **risks** may not be in proportion to one another because of differences in the age structures of populations.

2. Cancer in Western Australia, 2006

2.1 All cancers

2.1.1 Incidence


In 2006, there were 9692 new diagnoses of cancer in Western Australia, an apparent increase of 4.5% over a "current" figure for 2005 (9278 cases). There were 5457 cancers diagnosed in males (56%) and 4235 (44%) in females. Corresponding age-standardised incidence rates were 362 per 100,000 (males) and 270 per 100,000 (females). These rates were both slightly higher than the all-cancers ASRS reported for 2005.

The estimated lifetime risk of cancer to age 75 years was 1 in 3 for males and 1 in 4 for females. The cumulative incidence of cancer - the proportion of persons in whom cancer had been diagnosed by age 75 years - was 42.7% for males, 29.9% for females, both slightly higher than in 2005.

Most of the excess cancer risk in females between ages 30 and 50 was due to ovarian and breast cancers, while prostate cancer and lung cancer were responsible for the high male/female rate ratio (approximately 2) at ages over 65 years (Figure 1).

The proportion of all cancers with a microscopic diagnosis was high (94% in males and in females, stable over the last 5 years). Among the most common types, primary liver cancer was the most often diagnosed by non-histological methods in males (43%), and pancreatic cancer (43%) in females). Cancers of unknown primary site were also commonly diagnosed by non-microscopic methods.

Figure 1. Age-specific all-cancers incidence and mortality rates, Western Australia, 2006.



Additional sources of incidence data

In any year, the WA cancer statistics include a number of cases which were initially "hospital data only" records and were confirmed as true cancer cases following attempts to obtain more information. The 2006 data reported here include a higher than usual number of such cases, due to work piloted and described in *Cancer incidence and mortality in Western Australia, 2004*.⁵

In 2007 Registry staff investigated 1189 un-verified hospital-sourced "cases" for 2006, over a 5-month period. Results showed that 218 (18%) were not valid cancer cases, or at least not for WA; 540 (45%) were correct and the subject of an un-notified pathology test; 166 (14%) were correct but based on non-pathological methods of diagnosis; while no response was received, or information could be found, for 265 records (22%). Priorities for 2008 include resources to enhance such followup, and continued liaison with laboratories to obtain such un-reported results routinely.

2.1.2 Mortality

Among Western Australian residents in 2006, there were 2047 deaths due to cancer in males and 1523 in females (Table 1). Mortality ASRs were 123 deaths per 100,000 males (lower than in 2005 [127]) and 82 per 100,000 females (higher than in 2005 [78]). The estimated lifetime risk of death due to cancer before age 75 years was 1 in 8 for males and 1 in 12 for females. These rates and risks are statistically similar to those for 2005 and other recent years.

These deaths include 51 cases due to non-melanocytic skin cancers, increased by 30% since 2005. Of the cancers concerned, 42 (82%) were of the types (squamous and basal cell carcinomas) that are not included in incidence data (32 males, 10 females; 41 SCCs and one BCC).

In 2006, there were 22 cancer-related deaths in persons not normally resident in Western Australia (16 Australian, 6 from overseas); these are not included in the population-based mortality statistics in this report.

Other 2006 deaths recorded by the Cancer Registry included:

- Deaths due to benign tumours - 8 (4 of which were meningiomas or other CNS tumours)
- Deaths due to "uncertain malignant potential" lymphohaematopoietic neoplasms - 2
- Deaths due to "uncertain malignant potential" non-lymphohaematopoietic neoplasms - 4
- Deaths due to non-tumour-related causes among persons with a Registry tumour record - 862 males (increased since 2005), 635 females (almost unchanged).
- Deaths of unresolved cause among persons with a tumour record - 41 (26 males, 15 females).

Before the age of 75 years, a total of 14384 person-years of life were lost due to cancer among males and 12774 in females, both increased since 2005.

There was no significant change in the age-pattern of cancer mortality in 2006. Cancer death rates generally increased for both males and females from age 20 (Figure 1), with low case numbers at earlier ages. All-cancers death rates among males were consistently higher than in females at ages greater than 55 years.

2.1.3 Mortality to incidence ratios

Except in situations where incidence and/or mortality are changing rapidly, or notification of cancer is incomplete, the ratio of mortality to incidence for a cancer gives a crude indication of its impact. The 2006 mortality/incidence (M/I) rate ratio for prostate cancer was 0.12 and the ratio for breast cancer in females was 0.17. Lung cancer continues to have a far greater impact, with 2006 M/I ratios of 0.81 in males and 0.75 in females. All-cancers mortality/incidence ratios for 2006 were higher for males than for females (0.34 and 0.31). All these M/I ratios have been relatively stable over recent years.

2.2 Common cancers


2.2.1 Incidence

In females, breast cancer was the most common incident cancer (1244 cases, 29% of all cancers in females; ASR 86 per 100,000). This was followed by colorectal cancer (11%), melanoma of the skin (11%) and lung cancer (8%). There were an additional 230 newly-diagnosed cases of *in situ* breast carcinoma reported, slightly fewer than the all-time peak count of 265 cases in 2005. Previously, the female breast cancer incidence ASR fell by a small amount each year since 2002, from 87.4 successively to 84.6, 82.8 and 81.2 for 2005 but is now increased once more. In the light of comments in our recent reports regarding trends and screening, these changes in the rate of breast cancer should be monitored carefully.

The most common cancers in males were prostate cancer (1635 cases; 30%), melanoma (605 cases, 11%) and colorectal cancer (594 cases, 11%) (Table 1; Figure 2). Lung cancer was noted to be more common (ASR increased by 10%) in 2005 than in 2004, however the 2006 data show lung cancer returning to 4th ranking, with a 9% fall in the ASR in males. For all the major cancers affecting both males and females, males had a higher incidence than females.

Lymphomas, collectively the next most common cancer in both sexes, accounted for 4% of cancers in males and in females, with ASRs of 14 and 12 per 100,000. Cancers of unknown primary site were recorded in 180 males (3%, ASR 11) and 142 females (3%, ASR 7).

Figure 2. Cancer incidence, Western Australia, 2006: common cancers



Other common specific cancer types diagnosed included:

- Leukaemias - 134 cases in men (ASR 9.5), 91 in women (ASR 6.0)
- Bladder - 171 cases in men (ASR 10.3), 59 in women (ASR 2.7)
- Kidney - 151 cases in men (ASR 10.1), 70 in women (ASR 4.8)
- Pancreas - 105 cases in men (ASR 6.8), 105 in women (ASR 5.5)
- Stomach - 112 cases in men (ASR 6.8), 55 in women (ASR 2.9)

**(note that the "Bladder" grouping now includes renal pelvis and ureter tumours.)*

Other common cancer types in women were cancers of the uterus (160 cases, ASR 9.7), ovary (117 cases, ASR 7.8), thyroid (117 cases, ASR 8.9) and cervix (67 cases, ASR 4.8).


2.2.2 Mortality

The most common causes of cancer-related death in males were lung cancer (22%), prostate cancer (12%) and colorectal cancer (10%) (Table 1; Figure 3). Lung (17%), breast (15%) and colorectal cancer deaths (13%) were the most common in females.

In 2000, lung cancer first outranked breast cancer as a cause of death among women, however this appeared unusual at that time. While early detection may contribute to decreasing mortality from breast cancer, lung cancer is a significant cause of death in Western Australian women, being the most common cause of cancer death in women in each year since 2004 with over 30 more lung cancer deaths than breast cancer deaths in both 2005 and 2006. However, this pattern appears to reflect improved breast cancer incidence and mortality, rather than any dramatic change in female lung cancer rates.

Other major causes of cancer-related mortality included tumours of unknown primary site and pancreas in both sexes, melanoma, leukaemias and stomach cancer in males; and ovarian cancer and lymphomas in females. With minor changes, these results for 2006 are consistent with the usual common causes of cancer-related death in recent years.

Figure 3. Cancer mortality, Western Australia, 2006: common cancers



2.3 Cancer in different age groups


2.3.1 Cancer in children

In children under the age of 15 years, there were 44 cases of cancer diagnosed in 2006, 24 males and 20 females (Appendix 3A). The corresponding ASRs were 11.1 per 100,000 males, and 10.5 per 100,000 females, both lower than in 2005. The risk of a child developing cancer before the age of 15 years was 1 in 593 for boys and 1 in 656 for girls.

The estimated 0-14 years population in Western Australia in 2006 was 410,008 (211,788 males and 198,220 females).

Diagnoses are routinely coded and reported using ICD-O 3rd edition,⁴ but are also tabulated using the WHO-sponsored International Classification of Childhood Cancer (Version 3), into 12 major diagnostic groups based primarily on tumour morphology; these are shown in Appendix 3C. Please note that this classification includes additional tumour types that do not come under the usual definition of "cancers" (5 males, 1 female). The most common tumours diagnosed in children in 2006 are shown in Figure 4.

Figure 4. Cancer in children under 15 years of age, Western Australia, 2006: most common types (ICCC Version 3 - 50 cases).




There were 8 cancer-related deaths (2 males, 6 females) in children in 2006. Age-adjusted death rates were 1.0 per 100,000 in males (lower than in 2005) and 3.2 per 100,000 in females (also lower than in 2005). The estimated risk of death due to cancer before the age of 15 was 1 in 7062 for males, and 1 in 2168 for females.

2.3.2 Cancer in the 15-39 years age range


Incidence: In the 15 to 39 years age range, there were 513 cancer diagnoses in 2006 (219 males, ASR 53, 294 females, ASR 73) (Table 2). Melanoma was most common in males (61 cases, ASR 15) and breast cancer was most common in females (68 cases, ASR 215). Second-ranked cancers were testicular cancer in males (45 cases, 16% of all cancers) and melanoma in females (67 cases, 23% of all cancers) (Figure 5). Lymphomas and thyroid cancers were the next most common in females, with colorectal cancer and lymphomas following next in males.

Figure 5. Cancer incidence, Western Australia, 2006: common cancers in the 15 to 39 years age group



Mortality: Among persons aged 15 to 39 years, there were 67 cancer-related deaths in 2006, 29 in males and 38 in females (Table 3). Among males, the most common causes of cancer-related death were leukaemia (5 deaths), and melanoma, testicular cancer and brain cancers (3 deaths each) (Figure 6). In females, most common causes were breast cancer (12 deaths), leukaemias (5), brain cancers (4) and lymphomas (4). As cancer-related death in this age group is relatively uncommon, these 'rankings' remain very variable from year to year.


Figure 6. Cancer mortality, Western Australia, 2006: common cancers in the 15 to 39 years age group



2.3.3 Cancer in the 40-64 years age range


Incidence: In the age range 40 to 64 years, breast cancer continued to dominate reported incident cancers (777 cases, 42% of all female cancers in this age group, little-changed in the last 4 years) (Table 2; Figure 7). However, the number of prostate cancer cases in this age range increased by a greater proportion, from 556 in 2005 to 635 in 2006. The risk of cancer occurring in this age range was 1 in 6 for males and 1 in 7 for females. More cancers occurred in males than in females, with prostate cancer (31%), melanoma (13%) and colorectal cancer (10%) most common. In females, melanoma (12%) and colorectal cancer (8%) ranked highest after breast cancer.

Figure 7. Cancer incidence, Western Australia, 2006: common cancers in the 40 to 64 years age group



Mortality: In 2006, in the age range 40 to 64 years, lung cancer was, as in recent years, the most common cause of cancer-related death in males (124 deaths, age-adjusted rate of 37 per 100,000 males; apparently increasing) (Table 3; Figure 8). Other leading causes of death in males were colorectal cancer (61 deaths), pancreatic cancer (33), oesophageal cancer (31) and melanoma (30 deaths). Major causes among females were breast cancer (116 deaths), lung cancer (65 deaths) and colorectal cancer (41 deaths).

Figure 8. Cancer mortality, Western Australia, 2006: common cancers in the 40 to 64 years age group




2.3.4 Cancer in persons aged 65 and over

Incidence: Over the age of 65 years, prostate cancer (997 cases) outnumbered any other specific cancer type in either sex (Table 2; Figure 9) and accounted for 32% of diagnoses in males. Rates continue to rise in recent years, after major changes and unstable rates in the 1990s. Among females, breast cancer predominated (399 cases, 19%).

Other common cancer types in this age range were colorectal cancer (12% in males, 16% in females) and lung cancer (13%, 11%) (relatively stable over recent years). Melanoma of the skin was the fourth most common cancer type in males and in females (8% in both).

Figure 9. Cancer incidence, Western Australia, 2006: common cancers in the 65 years & over age group



Mortality: Over the age of 65 years, lung cancer was, as in recent years, the most common cause of cancer-related death in both sexes. Among males, lung cancer caused 332 deaths, at an age-adjusted rate 264 per 100,000 (considerably reduced since 2005); 22% of cancer-related deaths. Among females, it was responsible for 197 deaths at 131 per 100,000, 19% of all cancer deaths. Colorectal cancer ranked third in males (142 deaths, 10%) and second in females (155 deaths, 15%). Deaths due to prostate cancer ranked second in males (238 deaths, 16%). Breast cancer was the third most common cause of cancer-related death in females (101 deaths, 10%); a 20% reduction in deaths since 2005. Cancers of unknown primary site were also a major cause of death in this age range (139 deaths) (Figure 10).

Figure 10. Cancer mortality, Western Australia, 2006: common cancers in the 65 years & over age group




Table 2. Cancer incidence, Western Australia, 2006: leading types by sex and age group (ASR: age-adjusted rate)

15 to 39 years											
Males					Females						
	Cases	%	ASR 95%c.i.	Risk		Cases	%	ASR 95%c.i.	Risk		
Melanoma (skin)	61	27.9	15.4	11.5-	248	Breast	68	23.1	15.2	11.6-	219
Testis	35	16.0	8.6	5.7-	431	Melanoma (skin)	67	22.8	17.2	13.0-	216
Colorectal	17	7.8	4.0	2.1-	898	Lymphoma	30	10.2	8.5	5.4-	480
Colon	10	4.6	2.4	0.9-	1515	Lymphoma NOS	0		0.0	0 - (-
Rectum	7	3.2	1.5	0.4-	2203	Hodgkin lymphoma	20	6.8	6.0	3.3-	715
Lymphoma	17	7.8	4.2	2.2-	895	NHL	10	3.4	2.5	0.9-	1456
Lymphoma NOS	0		0.0	0 - (-	Thyroid gland	24	8.2	6.1	3.6-	608
Hodgkin lymphoma	4	1.8	1.1	0.0-	3707	Cervix	23	7.8	5.6	3.3-	632
NHL	13	5.9	3.1	1.4-	1179	Colorectal	11	3.7	2.8	1.1-	1300
Lip, gum & mouth	16	7.3	3.6	1.8-	950	Colon	7	2.4	1.7	0.4-	2056
Kidney	9	4.1	2.0	0.7-	1681	Rectum	4	1.4	1.1	0.0-	3537
Thyroid gland	9	4.1	2.2	0.7-	1694	Brain	9	3.1	2.0	0.7-	1636
Brain	8	3.7	2.1	0.6-	1872	Leukaemia	9	3.1	2.5	0.8-	1621
Leukaemia	7	3.2	1.7	0.4-	2155	Leukaemia NOS	0		0.0	0 - (-
Leukaemia NOS	0		0.0	0 - (-	Lymphoid leukaemia	3	1.0	0.9	0 - (4864
Lymphoid leukaemia	4	1.8	1.0	0.0-	3766	Myeloid leukaemia	6	2.0	1.6	0.3-	2431
Myeloid leukaemia	3	1.4	0.6	0 - (5036	Leukaemia, other	0		0.0	0 - (-
All cancers	219	100.0	53.3	46.1-	70	All cancers	294	100.0	72.8	64.4-	50

40 to 64 years											
Males					Females						
	Cases	%	ASR 95%c.i.	Risk		Cases	%	ASR 95%c.i.	Risk		
Prostate	635	30.6	185.6	171	19	Breast	777	42.0	235.2	219	17
Melanoma (skin)	276	13.3	80.3	70.8-	46	Melanoma (skin)	212	11.5	63.5	54.9-	62
Colorectal	213	10.3	62.4	54.0-	57	Colorectal	155	8.4	47.2	39.8-	75
Colon	126	6.1	36.8	30.3-	95	Colon	98	5.3	29.9	23.9-	117
Rectum	87	4.2	25.6	20.2-	138	Rectum	56	3.0	17.0	12.6-	212
Lung	148	7.1	44.2	37.1-	78	Lung	97	5.2	28.8	23.0-	119
Lymphoma	84	4.0	24.4	19.1-	154	Thyroid gland	69	3.7	21.2	16.2-	185
Lymphoma NOS	1	0.0	0.3	0 - (*	Uterus	59	3.2	17.5	13.0-	208
Hodgkin lymphoma	4	0.2	1.1	0.0-	3629	Lymphoma	57	3.1	17.2	12.7-	232
NHL	79	3.8	22.9	17.8-	162	Lymphoma NOS	1	0.1	0.3	0 - (*
Kidney	74	3.6	21.8	16.8-	169	Hodgkin lymphoma	3	0.2	0.9	0 - (5104
Unknown primary	61	2.9	18.0	13.4-	204	NHL	53	2.9	15.9	11.6-	247
Lip, gum & mouth	59	2.8	17.3	12.9-	217	Ovary	48	2.6	14.2	10.2-	265
Leukaemia	42	2.0	12.5	8.7-	295	Pancreas	32	1.7	9.8	6.4-	362
Leukaemia NOS	0		0.0	0 - (-	Leukaemia	29	1.6	8.9	5.6-	398
Lymphoid leukaemia	28	1.3	8.1	5.1-	446	Leukaemia NOS	0		0.0	0 - (-
Myeloid leukaemia	14	0.7	4.4	2.1-	867	Lymphoid leukaemia	20	1.1	6.2	3.5-	573
All cancers	2077	100.0	608.4	582	6	All cancers	1851	100.0	559.3	534	7

65 years and over											
Males					Females						
	Cases	%	ASR 95%c.i.	Risk		Cases	%	ASR 95%c.i.	Risk		
Prostate	997	31.8	872.2	816	13	Breast	399	19.3	301.2	269	35
Lung	394	12.6	330.6	297	34	Colorectal	320	15.5	209.6	184	58
Colorectal	364	11.6	317.1	283	34	Colon	249	12.0	161.5	139	76
Colon	226	7.2	194.7	168	60	Rectum	70	3.4	46.9	34.8-	253
Rectum	138	4.4	122.5	101	79	Lung	230	11.1	164.8	142	68
Melanoma (skin)	268	8.5	229.4	201	47	Melanoma (skin)	168	8.1	124.7	104	82
Bladder & urinary tract	132	4.2	105.7	86.9	126	Unknown primary	110	5.3	63.0	49.8-	255
Unknown primary	116	3.7	88.4	71.7	207	Uterus	98	4.7	71.9	56.3-	153
Lymphoma	101	3.2	87.5	69.8	133	Lymphoma	94	4.5	64.7	50.3-	185
Lymphoma NOS	4	0.1	3.1	0 - (7423	Lymphoma NOS	4	0.2	2.5	0 - (7355
Hodgkin lymphoma	2	0.1	2.0	0 - (7423	Hodgkin lymphoma	3	0.1	1.5	0 - (*
NHL	95	3.0	82.4	65.2-	138	NHL	87	4.2	60.8	46.7-	190
Stomach	80	2.6	65.1	50.2-	189	Pancreas	73	3.5	43.9	32.7-	274
Leukaemia	77	2.5	65.6	50.3-	175	Ovary	61	2.9	48.7	35.4-	197
Leukaemia NOS	4	0.1	2.3	0 - (*	Leukaemia	50	2.4	33.8	23.3-	352
Lymphoid leukaemia	47	1.5	41.2	29.0-	257	Leukaemia NOS	2	0.1	0.7	0 - (*
Myeloid leukaemia	26	0.8	22.0	13.2-	545	Lymphoid leukaemia	34	1.6	23.7	14.9-	527
All cancers	3137	100.0	2668.5	2572	5	All cancers	2070	100.0	1432.9	1365	8

Table 3. Cancer mortality, Western Australia, 2006: leading types by sex and age group (ASR: age-adjusted rate)

15 to 39 years											
Males						Females					
	Deaths	%	ASR	95%c.i.	Risk		Deaths	%	ASR	95%c.i.	Risk
Leukaemia	5	17.2	1.2	0.1-2.3	2994	Breast	12	31.6	2.7	1.2-4.2	1243
Leukaemia NOS	0		0.0	0 - 0.0	-	Leukaemia	5	13.2	1.4	0.2-2.6	2838
Lymphoid leukaemia	2	6.9	0.5	0 - 1.2	7562	Leukaemia NOS	0		0.0	0 - 0.0	-
Myeloid leukaemia	3	10.3	0.7	0 - 1.6	4955	Lymphoid leukaemia	2	5.3	0.6	0 - 1.5	6749
Leukaemia, other	0		0.0	0 - 0.0	-	Myeloid leukaemia	3	7.9	0.7	0 - 1.6	4897
Melanoma (skin)	3	10.3	0.7	0 - 1.6	4955	Leukaemia, other	0		0.0	0 - 0.0	-
Testis	3	10.3	0.8	0 - 1.7	5024	Brain	4	10.5	0.9	0.0-1.8	3615
Brain	3	10.3	0.8	0 - 1.8	4784	Lymphoma	4	10.5	1.2	0.0-2.3	3485
Stomach	2	6.9	0.4	0 - 1.0	7865	Lymphoma NOS	0		0.0	0 - 0.0	-
Lung	2	6.9	0.5	0 - 1.2	7445	Hodgkin lymphoma	0		0.0	0 - 0.0	-
Penis	2	6.9	0.4	0 - 1.0	7629	NHL	4	10.5	1.2	0.0-2.3	3485
Colorectal	1	3.4	0.2	0 - 0.6	*	Stomach	2	5.3	0.4	0 - 1.0	7642
Colon	1	3.4	0.2	0 - 0.6	*	Melanoma (skin)	2	5.3	0.5	0 - 1.3	7168
Rectum	0		0.0	0 - 0.0	-	Cervix	2	5.3	0.4	0 - 1.0	7642
Lip, gum & mouth	1	3.4	0.2	0 - 0.6	*	Unknown primary	2	5.3	0.4	0 - 1.0	7642
Pharynx	1	3.4	0.2	0 - 0.6	*	Oesophagus	1	2.6	0.2	0 - 0.6	*
Nasopharynx	1	3.4	0.2	0 - 0.6	*	Anus	1	2.6	0.2	0 - 0.6	*
All cancers	29	100.0	7.0	4.4-9.6	521	All cancers	38	100.0	9.2	6.2-12.1	386

40 to 64 years											
Males						Females					
	Deaths	%	ASR	95%c.i.	Risk		Deaths	%	ASR	95%c.i.	Risk
Lung	124	23.7	36.7	30.2-43.2	94	Breast	116	27.2	34.8	28.4-41.2	103
Colorectal	61	11.7	18.2	13.6-22.8	193	Lung	65	15.2	19.8	14.9-24.6	174
Colon	33	6.3	10.0	6.6-13.4	358	Colorectal	41	9.6	12.7	8.8-16.6	304
Rectum	28	5.4	8.2	5.1-11.3	417	Colon	25	5.9	7.8	4.7-10.8	484
Pancreas	33	6.3	9.5	6.2-12.8	352	Rectum	16	3.7	4.9	2.5-7.3	814
Oesophagus	31	5.9	9.2	5.9-12.5	387	Pancreas	24	5.6	7.3	4.4-10.3	493
Melanoma (skin)	30	5.7	8.8	5.6-12.0	433	Ovary	24	5.6	7.0	4.2-9.9	511
Brain	27	5.2	7.8	4.8-10.7	475	Melanoma (skin)	16	3.7	4.7	2.4-7.0	776
Liver	22	4.2	6.3	3.7-9.0	612	Uterus	14	3.3	4.5	2.1-6.8	792
Stomach	21	4.0	6.3	3.6-9.0	575	Unknown primary	13	3.0	3.7	1.7-5.8	957
Leukaemia	21	4.0	6.1	3.5-8.8	570	Stomach	12	2.8	3.5	1.5-5.5	1045
Leukaemia NOS	1	0.2	0.3	0 - 0.8	*	Brain	12	2.8	3.5	1.5-5.5	991
Lymphoid leukaemia	6	1.1	1.6	0.3-3.0	2148	Cervix	11	2.6	3.2	1.3-5.1	1214
Myeloid leukaemia	14	2.7	4.2	2.0-6.4	821	Leukaemia	11	2.6	3.4	1.4-5.5	1071
Leukaemia, other	0		0.0	0 - 0.0	-	Leukaemia NOS	0		0.0	0 - 0.0	-
Unknown primary	18	3.4	5.4	2.9-7.9	649	Lymphoid leukaemia	3	0.7	1.0	0 - 2.2	3526
Lymphoma	16	3.1	4.6	2.3-6.8	742	Myeloid leukaemia	8	1.9	2.4	0.7-4.1	1537
All cancers	523	100.0	153.7	140-167	23	All cancers	427	100.0	128.7	116-141	28


65 years and over											
Males						Females					
	Deaths	%	ASR	95%c.i.	Risk		Deaths	%	ASR	95%c.i.	Risk
Lung	332	22.2	264.3	235-294	49	Lung	197	18.7	131.5	111-152	95
Prostate	238	15.9	173.6	151-197	123	Colorectal	155	14.7	97.6	80.5-115	133
Colorectal	142	9.5	112.6	93.3-132	127	Colon	105	10.0	63.5	49.9-77.1	229
Colon	91	6.1	70.6	55.4-85.8	243	Rectum	50	4.8	34.0	23.8-44.3	315
Rectum	51	3.4	42.0	30.0-54.1	264	Breast	101	9.6	66.4	52.1-80.8	183
Pancreas	80	5.4	65.9	50.8-81.0	192	Pancreas	78	7.4	46.5	34.9-58.0	315
Bladder & urinary tract	66	4.4	50.3	37.7-62.8	407	Unknown primary	77	7.3	43.4	32.5-54.3	394
Unknown primary	62	4.2	45.2	33.5-57.0	589	Ovary	47	4.5	36.8	25.4-48.2	253
Stomach	60	4.0	45.4	33.4-57.3	361	Lymphoma	43	4.1	22.7	15.2-30.2	952
Leukaemia	51	3.4	39.6	28.2-50.9	367	Lymphoma NOS	1	0.1	0.4	0 - 1.1	*
Leukaemia NOS	4	0.3	2.3	0 - 4.6	*	Hodgkin lymphoma	0		0.0	0 - 0.0	-
Lymphoid leukaemia	18	1.2	14.3	7.3-21.2	932	NHL	42	4.0	22.3	14.8-29.8	952
Myeloid leukaemia	29	1.9	23.0	14.3-31.7	606	Bladder & urinary tract	30	2.9	13.8	8.7-18.9	5923
Leukaemia, other	0		0.0	0 - 0.0	-	Oesophagus	29	2.8	16.9	10.1-23.7	924
Melanoma (skin)	50	3.3	38.1	27.1-49.2	386	Stomach	29	2.8	16.8	10.1-23.6	896
Mesothelioma	46	3.1	37.8	26.5-49.1	350	Melanoma (skin)	27	2.6	18.2	10.7-25.7	569
Lymphoma	46	3.1	39.0	27.3-50.8	350	Myelodysplastic diseases	26	2.5	15.1	8.5-21.7	952
All cancers	1493	100.0	1171.2	1110-1233	13	All cancers	1052	100.0	656.1	612-700	21

3. Cancer in Western Australia: special topics

3.1 Death Certificate Only cancers

“Death certificate only” (DCO) cancer records are those based solely on a death certificate (or electronic mortality record). Having a low proportion of DCO cases is widely regarded as an important index of data quality in a Cancer Registry. In Western Australia, there were 36 DCO cancers recorded for 2006, representing only 0.37% of all cancers (low, but increased from 0.26% in 2005 and 0.20% in 2004) (Figure 11).


Figure 11. Death Certificate Only (DCO) cancers, 2006: common types (36 cases)



The Registry continues to use computerised hospital discharge data to reduce letter-based enquiries and casenote review, if the data are consistent. There were 149 such "DC and HMDS" cases recorded for 2006, fewer than in 2005, with the date of diagnosis being taken from the hospital discharge date. The most common types were cancers of the lung and pancreas, and cancers of unknown primary site (Figure 12).

As the discharge data lack a true diagnosis date or address at diagnosis, and basis of diagnosis, these data are treated as being less reliable than those sourced from clinical notes and pathology reports. However, the process appears cost-effective in improving timeliness. As noted in our recent reports, an audit was needed - and was performed in 2006, and repeated in 2007.

Figure 12. "DC & HMDS" cancers, 2006: common types (149 cases)



4. References

- 1 Threlfall TJ, Thompson JR, Olsen N (2007). *Cancer incidence and mortality in Western Australia, 2005*. Department of Health, Western Australia, Perth. Statistical series number 81.
- 2 Segi M (1960) *Cancer mortality for selected sites in 24 countries (1950-1957)*. Sendai, Japan, Tohoku University Press.
- 3 Population by age and sex. 2001 Census Edition - Final. Australian Bureau of Statistics, Canberra, cat. 3201.0
- 4 World Health Organization (2000) *ICD-O: International classification of diseases for oncology* (Third Edition). WHO, Geneva.
- 5 Threlfall TJ, Thompson JR, Olsen N (2006). *Cancer incidence and mortality in Western Australia, 2004*. Department of Health, Western Australia, Perth. Statistical series number 76.

LIST OF APPENDICES

Note that Information for Appendices 1 and 2, listed here but not printed, is available on the Internet, as produced for the 2005 report, at <http://www.health.wa.gov.au/wacr/datr05.html>

1	About The Western Australian Cancer Registry	
1A	Overview and technical issues	
	History and role	A1-1
	Registry scope	A1-1
	Legislative basis	A1-1
	Sources of data	A1-2
	Data handling and maintenance	A1-2
	Coding practices	A1-3
	Quality assurance	A1-5
	Uses of Cancer Registry data	A1-5
1B	Current issues	
	Registry staffing and workload	A1-6
	Assessment of current notification system and Regulations	A1-6
2	Technical and miscellaneous information	
2A	Glossary	A2-1
2B	Statistical methods and formulae	A2-2
2C	Populations and geographic areas	A2-4
2D	Confidentiality guidelines	A2-8
2E	Cancer Notification Regulations	A2-9
2F	Cancer codes	A2-11
2G	WACR publications	A2-13
2H	Guide to tables in Appendix 3	A2-14
3	Cancer incidence and mortality in Western Australia, 2006	
3A	Cancer incidence, Western Australia, 2006: numbers and rates by type, sex and age group	A3-1
3B	Cancer mortality, Western Australia, 2006: numbers and rates by type, sex and age group	A3-11
3C	Childhood cancer incidence, Western Australia, 2006: ICD-O 3rd Revision classification scheme	A3-21
3D	Cancer incidence, Western Australia, 2006: leading types by sex and geographic area	A3-25
3E	Cancer mortality, Western Australia, 2006: leading types by sex and geographic area	A3-30

- Notes -

Appendix 3A now contains an incidence data summary for the most common cancers on page A3-10.

Appendix 3A. Cancer incidence, Western Australia, 2006

Age	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+ u/k	Total	ASR	95% c.i.	TD% CumInc	Risk	ASR2	
Lip, gum & mouth (C000-C069) (not C01-C02)																									
M				1	1	1	7	7	9	9	12	14	15	11	7	10	5	6	115	8.1	6.6-9.6	100.0	0.8	119	11.5 (9.4-13.6)
			1.3	1.3	1.3	1.4	9.5	8.9	11.4	11.8	16.9	21.4	30.8	29.6	25.0	44.3	34.9	68.1							
F			1	1	1	1	1	2	6	1	9	4	4	6	9	7	2	5	55	3.6	2.6-4.6	100.0	0.4	230	5.2 (3.8-6.6)
			1.4	1.4	1.4	1.4	1.4	1.3	2.6	7.9	1.4	14.4	8.7	16.3	30.4	27.1	10.1	26.8							
Tongue (C010-C029)																									
M				1	1	2	3	5	4	4	4	4	3	3	1	2	2	2	28	2.0	1.2-2.7	100.0	0.2	475	2.7 (1.7-3.7)
			1.4	1.3	2.5	3.9	7.1	6.1	8.2	8.1	8.2	8.1	8.2	8.1	3.6	8.9	14.0								
F			2	1	2	2	2	2	2	1	3	3	1	3	3	1	2	2	19	1.2	0.6-1.8	100.0	0.1	872	1.8 (1.0-2.6)
			2.6	1.3	2.6	2.9	3.2	3.2	2.2	2.2	2.2	2.2	2.2	2.2	11.6	5.1	10.7								
Parotid gland (C070-C079)																									
M				1	1	1	1	1	1	1	1	1	1	1	2	2	2	2	9	0.6	0.2-1.0	100.0	0.1	1304	0.9 (0.3-1.5)
			1.3	1.3	1.3	1.4	1.5	1.5	1.5	1.5	1.5	1.5	1.5	2.7	7.1	14.0									
F			2	1	2	2	2	2	1	3	3	3	1	3	3	1	2	2	3	0.2	0-0.4	100.0	0.0	4474	0.3 (0-0.6)
			2.9	1.6	2.9	1.6	2.9	1.6	2.9	1.6	2.9	1.6	2.9	1.6	11.6	5.1	10.7								
Major salivary glands (not parotid) (C080-C089)																									
M															1	1			2	0.2	0-0.4	100.0	0.0	3557	0.2 (0-0.5)
															2.1	3.6									
F			1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	2	0.2	0-0.4	100.0	0.0	4993	0.2 (0-0.5)
			1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	2.7	2.7									
Pharynx (C090-C149) (not C11)																									
M			1	2	4	6	10	9	7	7	9	4	3	7	9	4	3	3	55	3.8	2.8-4.8	98.0	0.5	196	5.3 (3.9-6.8)
			1.3	2.5	5.2	8.5	15.3	18.5	18.9	32.1	17.7	20.9													
F			3	1	1	1	2	3	3	3	1	2	2	3	1	2	1	2	13	0.9	0.4-1.4	100.0	0.1	1026	1.2 (0.5-1.8)
			3.9	1.4	1.6	1.6	4.4	8.2	8.2	8.2	5.1	10.7													
Nasopharynx (C110-C119)																									
M			1	1	1	4	4	4	1	1	1	1	1	1	1	1	1	1	6	0.4	0.1-0.7	100.0	0.1	1987	0.5 (0.1-0.9)
			1.3	1.3	1.3	6.1	6.1	6.1	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.7							
F			1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	0.1	0-0.2	100.0	0.0	*	0.1 (0-0.3)
			1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3							
Oesophagus (C150-C159)																									
M			1	1	6	8	12	12	13	14	14	9	9	9	9	9	9	6	91	6.0	4.7-7.3	99.0	0.7	134	9.4 (7.5-11.4)
			1.3	1.3	7.8	11.3	18.3	24.7	35.0	49.9	39.9	39.9	62.8	68.1											
F			1	1	1	1	1	1	2	4	4	4	5	15	15	15	15	15	36	1.6	1.0-2.2	94.0	0.2	652	3.1 (2.1-4.2)
			1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4							
Stomach (C160-C169)																									
M			1	2	4	7	11	7	13	20	21	15	11	11	20	21	15	11	112	6.8	5.5-8.1	94.0	0.8	128	12.4 (10.0-14.7)
			1.3	2.5	5.2	9.9	16.8	14.4	35.0	71.3	93.0	104.7	124.8												
F			1	2	3	3	6	3	4	7	7	11	8	8	7	11	8	8	55	2.9	2.1-3.7	95.0	0.3	319	5.1 (3.7-6.4)
			1.4	2.6	3.9	4.3	9.6	6.5	10.9	23.6	27.1	55.7	42.9												
Small intestine (C170-C179)																									
M						2	5	3	1	2	2	1	2	1	2	1	2	2	16	1.1	0.5-1.6	100.0	0.1	757	1.6 (0.8-2.4)
						2.8	7.6	6.2	2.7	7.1	7.1	7.0	22.7												
F			1	1	2	1	1	6	3	1	3	1	3	1	3	1	3	1	20	1.4	0.8-2.1	95.0	0.2	609	1.9 (1.1-2.8)
			1.3	1.3	2.6	1.4	1.6	13.1	8.2	3.4	11.6	5.1													

Appendix 3A. Cancer incidence, Western Australia, 2006

Age	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85 + u/k	Total	ASR	95% c.i.	TD% CumInc	Risk	ASR2			
Lung, bronchus & trachea (C330-C349)																											
M				1	1.3		3	4.1	4	5.1	16	19	38	71	84	106	85	79	40	546	34.6	31.6-37.6	86.0	4.3	24	59.3 (54.2-64.3)	
F				1	1.3		1	1	3	8	11	43	32	46	51	70	42	21		329	18.9	16.7-21.1	87.0	2.3	43	31.3 (27.9-34.7)	
Thymus (C370-C379)																											
M													1	2.1						1	0.1	0-0.2	100.0	0.0	9726	0.1 (0-0.3)	
F																				0							
Pleura, heart & mediastinum (C380-C389)																											
M				1	1.3							1	1.5		1	3.6				3	0.2	0-0.5	100.0	0.0	3132	0.3 (0-0.6)	
F												1	1							1	0.1	0-0.2	100.0	0.0	*	0.1 (0-0.2)	
Bones, joints & articular cartilages (C400-C419)																											
M				1	1.3		2	2.7	2	2.5	1	1	2.1	1	2.7		1			10	0.8	0.3-1.3	100.0	0.1	1438	1 (0.4-1.6)	
F				1	1.6		1	1.4	1	1.3		1	2.2			3	10.1	5.4		9	0.8	0.2-1.4	78.0	0.1	1107	0.9 (0.3-1.5)	
Skin (melanoma only) (C440-C449; M-8720 - 8790)																											
M				7	9.2	12	13	17.6	20	25.4	33	54	78	76	72	65	68	45	18	605	41.8	38.4-45.3	100.0	4.7	22	60.9 (56.0-65.8)	
F				5	7.1	10	10	17.0	16	25	35	52	38	54	37	43	40	23	25	447	31.0	28.0-34.0	100.0	3.3	31	42.5 (38.5-46.5)	
Skin (not melanoma/SCC/BCC) (C440-C449)																											
M				1	1.4	9	13	14.8	3	3.8	5	3	4.6	4	7	6	5	12	10	60	3.7	2.7-4.7	100.0	0.4	286	6.8 (5.0-8.5)	
F				1	1.4	2	2	14.8	2	2	2	3	4.8	6	2.7	6.8	19.4	30.4	53.7	43	2.3	1.6-3.1	100.0	0.2	488	3.9 (2.7-5.0)	
Mesothelioma (M905; ICD10 C45)																											
M				1	1.3	7	13	17.0	20	25.4	33	54	78	76	72	65	68	45	18	65	3.9	2.9-4.9	98.0	0.4	251	6.9 (5.2-8.6)	
F				1	1.3	2	2	17.0	16	25	35	52	38	54	37	43	40	23	25	10	0.7	0.2-1.1	100.0	0.1	1040	1 (0.4-1.6)	
Kaposi sarcoma (M914; ICD10 C46)																											
M				1	1.3	7	13	17.0	20	25.4	33	54	78	76	72	65	68	45	18	3	0.2	0-0.4	100.0	0.0	4740	0.3 (0-0.6)	
F				1	1.3	2	2	17.0	16	25	35	52	38	54	37	43	40	23	25	3	0.1	0-0.2	100.0	0.0	*	0.2 (0-0.5)	
Nervous system, peripheral/autonomic (C470-C479)																											
M				1	1.3	7	13	17.0	20	25.4	33	54	78	76	72	65	68	45	18	0							
F				1	1.3	2	2	17.0	16	25	35	52	38	54	37	43	40	23	25	0							

Appendix 3A. Cancer incidence, Western Australia, 2006

Age	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85 +	u/k	Total	ASR	95% c.i.	TD%	CumInc	Risk	ASR2	
LYMPHOMAS																											
Lymphoma, NOS / unclassifiable																											
M				1									1	1	1	1	1	1	1	5	0.3	0.0-0.6	40.0	0.0	5047	0.6 (0.1-1.1)	
F				1.3									2.7	4.4	7	11.3				5	0.3	0.0-0.5	100.0	0.0	4956	0.5 (0.1-0.8)	
Hodgkin lymphoma																											
M	2	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	12	1.1	0.4-1.7	100.0	0.1	1228	1.2 (0.5-1.9)	
F	2.7	1.3	2.8	1.3	1.3	1.3	1.4	1.5	2.7	11.3										28	2.8	1.7-3.9	96.0	0.2	575	2.7 (1.7-3.8)	
All NHL																											
M	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	190	13.0	11.1-15.0	98.0	1.5	69	19.7 (16.8-22.5)	
F	2.8	1.3	1.3	1.3	1.3	1.4	1.5	2.7	11.3											150	9.1	7.6-10.7	97.0	1.0	100	14.1 (11.8-16.4)	
NHL, mature B cell																											
M	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	139	9.5	7.9-11.2	98.0	1.1	93	14.3 (11.8-16.7)	
F	1.4	1.3	1.3	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	114	7.0	5.6-8.4	98.0	0.8	129	10.8 (8.8-12.8)	
NHL, mature T/NK cell																											
M	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	26	1.9	1.1-2.6	100.0	0.2	430	2.6 (1.6-3.6)	
F	1.4	1.3	1.3	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	7	0.5	0.1-0.8	100.0	0.1	1705	0.7 (0.2-1.2)	
NHL, precursor cell lymphoblastic																											
M	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	0.1	0 - 0.4	100.0	0.0	*	0.1 (0 - 0.3)	
F	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	3	0.2	0 - 0.5	100.0	0.0	4864	0.3 (0 - 0.6)	
NHL, other/unclassifiable																											
M	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	24	1.5	0.9-2.1	96.0	0.1	758	2.8 (1.6-3.9)	
F	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	26	1.5	0.8-2.1	88.0	0.1	685	2.4 (1.5-3.3)	
Lymphomas (all)																											
M	2	3	1	2	4	1	9	13	11	18	23	19	27	22	22	14	16			207	14.4	12.4-16.4	97.0	1.6	65	21.5 (18.5-24.4)	
F	2.8	4.0	1.3	2.6	5.7	1.4	11.4	16.5	14.4	25.4	35.1	39.1	72.8	78.5	97.4	97.7	181.5			183	12.2	10.3-14.1	97.0	1.2	84	17.3 (14.8-19.8)	
MYELOMA																											
Myeloma/plasma cell tumours																											
M																				56	3.5	2.6-4.5	79.0	0.4	261	6.1 (4.4-7.7)	
F																				41	2.4	1.6-3.1	90.0	0.3	339	3.8 (2.6-5.0)	

Appendix 3A. Cancer incidence, Western Australia, 2006

Age	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+ u/k	Total	ASR	95% c.i.	TD% CumInc	Risk	ASR2	
LEUKAEMIAS																									
Leukaemias, NOS/unclassifiable																									
M																									
F																									
Leukaemias, lymphoid, all																									
M	1	3	1	1	1	1	2	4	4	4	9	8	8	13	12	11	6	5							
F	1.5	4.3	1.3	1.3	1.3	1.3	2.7	3.8	5.2	5.6	13.7	16.5	16.5	35	42.8	48.7	41.9	56.7							
Leukaemias, lymphoid, acute																									
M	1	3	1	1	1	1	1	2	3	4	2	4	8	9	4	8	4	9							
F	1.5	4.3	1.3	1.3	1.3	1.4	1.4	1.3	2.6	2.6	4.3	8.0	17.4	24.5	13.5	31.0	20.3	48.3							
Leukaemias, lymphoid, chronic																									
M	2	1	1	1	1	1	1	3	4	3	4	8	10	10	12	8	5	5							
F	3.2	1.5	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.6	1.6	3.1	8.2											
Leukaemias, lymphoid, other/NOS																									
M	1						1	1	3	1	3	3	3	3	3	3	1	1							
F	1.4						1.4	4.6	8.1	13.3	7.0														
Leukaemias, myeloid, all																									
M	1	2	2	1	1	1	2	1	1	5	1	1	6	7	5	7	4	3							
F	1.5	2.7	2.7	1.3	1.3	1.3	2.7	1.3	6.5	1.4	1.5	12.3	18.9	17.8	31.0	27.9	34.0								
Leukaemias, myeloid, acute																									
M	1	2	2	1	1	1	1	3	3	3	2	3	2	3	2	4	1	4							
F	1.5	2.8	2.8	1.5	1.5	1.5	1.5	3.9	1.3	4.3	3.2	6.5	5.4	13.5	3.9	20.3	16.1								
Leukaemias, myeloid, chronic																									
M	1	1	1	1	1	1	1	1	1	4	1	3	5	5	3	2	3								
F	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	5.2	1.5	6.2	13.5	17.8	13.3	14.0	34.0								
Leukaemias, myeloid, other/NOS																									
M	1	1	1	1	1	1	1	1	1	1	1	2	2	2	3	3	3								
F	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.6	2.2	4.4	10.1	15.2	16.1									
Leukaemias, myeloid, other/NOS																									
M	1	1	1	1	1	1	1	1	1	1	1	2	2	2	3	3	1								
F	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.6	2.2	4.4	10.1	15.2	16.1									
Leukaemias, myeloid, other/NOS																									
M	1	1	1	1	1	1	1	1	1	1	1	2	2	2	3	3	1								
F	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.6	2.2	4.4	10.1	15.2	16.1									
Leukaemias, myeloid, other/NOS																									
M	1	1	1	1	1	1	1	1	1	1	1	2	2	2	3	3	1								
F	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.6	2.2	4.4	10.1	15.2	16.1									
Leukaemias, myeloid, other/NOS																									
M	1	1	1	1	1	1	1	1	1	1	1	2	2	2	3	3	1								
F	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.6	2.2	4.4	10.1	15.2	16.1									
Leukaemias, myeloid, other/NOS																									
M	1	1	1	1	1	1	1	1	1	1	1	2	2	2	3	3	1								
F	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.6	2.2	4.4	10.1	15.2	16.1									
Leukaemias, myeloid, other/NOS																									
M	1	1	1	1	1	1	1	1	1	1	1	2	2	2	3	3	1								
F	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.6	2.2	4.4	10.1	15.2	16.1									
Leukaemias, myeloid, other/NOS																									
M	1	1	1	1	1	1	1	1	1	1	1	2	2	2	3	3	1								
F	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.6	2.2	4.4	10.1	15.2	16.1									
Leukaemias, myeloid, other/NOS																									
M	1	1	1	1	1	1	1	1	1	1	1	2	2	2	3	3	1								
F	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.6	2.2	4.4	10.1	15.2	16.1									
Leukaemias, myeloid, other/NOS																									
M	1	1	1	1	1	1	1	1	1	1	1	2	2	2	3	3	1								
F	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.6	2.2	4.4	10.1	15.2	16.1									
Leukaemias, myeloid, other/NOS																									
M	1	1	1	1	1	1	1	1	1	1	1	2	2	2	3	3	1								
F	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.6	2.2	4.4	10.1	15.2	16.1									
Leukaemias, myeloid, other/NOS																									
M	1	1	1	1	1	1	1	1	1	1	1	2	2	2	3	3	1								
F	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.6	2.2	4.4	10.1	15.2	16.1									
Leukaemias, myeloid, other/NOS																									
M	1	1	1	1	1	1	1	1	1	1	1	2	2	2	3	3	1								
F	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.6	2.2	4.4	10.1	15.2	16.1									
Leukaemias, myeloid, other/NOS																									
M	1	1	1	1	1	1	1	1	1	1	1	2	2	2	3	3	1								
F	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.6	2.2	4.4	10.1	15.2	16.1									
Leukaemias, myeloid, other/NOS																									
M	1	1	1	1	1	1	1	1	1	1	1	2	2	2	3	3	1								
F	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.6	2.2	4.4	10.1	15.2	16.1									
Leukaemias, myeloid, other/NOS																									
M	1	1	1	1	1	1	1	1	1	1	1	2	2	2	3	3	1								
F	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.6	2.2	4.4	10.1	15.2	16.1									
Leukaemias, myeloid, other/NOS																									
M	1	1	1	1	1	1	1	1	1	1	1	2	2	2	3	3	1								
F	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.6	2.2	4.4	10.1	15.2	16.1									
Leukaemias, myeloid, other/NOS																									
M	1	1	1	1	1	1	1	1	1	1	1	2	2	2	3	3	1								
F	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.6	2.2	4.4	10.1	15.2	16.1									
Leukaemias, myeloid, other/NOS																									
M	1	1	1	1	1	1	1	1	1	1	1	2	2	2	3	3	1								
F	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.6	2.2	4.4	10.1	15.2	16.1									
Leukaemias, myeloid, other/NOS																									
M	1	1	1	1	1	1	1	1	1	1	1	2	2	2	3	3	1								
F	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.6	2.2	4.4	10.1	15.2	16.1									
Leukaemias, myeloid, other/NOS																									
M	1	1	1	1	1	1	1	1	1	1	1	2	2	2	3	3	1								
F	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.6	2.2	4.4	10.1	15.2	16.1									
Leukaemias, myeloid, other/NOS																									
M	1	1	1	1	1	1	1	1	1	1	1	2	2	2	3	3	1								
F	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.6	2.2	4.4	10.1	15.2	16.									

Appendix 3B. Cancer mortality, Western Australia, 2006

Age	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+	Total	ASR	95% c.i.	PYLL	CumInc	Risk	ASR2	
Lip, gum & mouth (C000-C069) (not C01 C02)																										
M								1	1	2		3	3	2	2	1	2	1	18	1.2	0.6-1.8	216.5	0.1	704	1.8 (1.0-2.7)	
								1.3	1.3	2.6		4.6	6.2	5.4	7.1	4.4	14.0	11.3								
F															1			3	4	0.1	0-0.3	2.4	0.0	5923	0.3 (0.0-0.7)	
															3.4			16.1								
Tongue (C010-C029)																										
M									1		2	3	2	1	2				11	0.8	0.3-1.3	154.0	0.1	885	1 (0.4-1.6)	
									1.3		2.8	4.6	4.1	2.7	7.1											
F											1	2				2		2	7	0.3	0.1-0.6	54.5	0.0	4313	0.6 (0.2-1.1)	
											1.4	3.2				7.8		10.7								
Parotid gland (C070-C079)																										
M												1			1	1			3	0.1	0-0.3	16.0	0.0	*	0.3 (0-0.7)	
												1.5			4.4	7.0										
F																		1	1	0.0	0-0.1	0.0	0.0	*	0.1 (0-0.2)	
																		5.4								
Major salivary glands (not parotid) (C080-C089)																										
M																		1	1	0.1	0-0.2	0.0	0.0	*	0.2 (0-0.5)	
																		11.3								
F										1									1	0.1	0-0.2	26.0	0.0	*	0.1 (0-0.3)	
										1.3																
Pharynx (C090-C149) (not C11)																										
M								1			3	2	1	4	4	2	1		18	1.1	0.6-1.6	122.3	0.1	743	1.9 (1.0-2.9)	
								1.3			4.6	4.1	2.7	14.3	17.7	14.0	11.3									
F											1		1	1	1	1			5	0.3	0.0-0.5	26.1	0.0	2598	0.5 (0.1-0.9)	
											1.6		2.7	3.4	3.9	5.1										
Nasopharynx (C110-C119)																										
M							1				1	1		1			1		5	0.3	0.0-0.6	83.2	0.0	2865	0.5 (0.1-0.9)	
							1.4				1.4	1.5		2.7			7.0									
F																			0					-		
Oesophagus (C150-C159)																										
M								1		5	7	7	12	10	13	7	8	3	73	4.9	3.7-6.0	656.9	0.6	159	7.5 (5.8-9.3)	
								1.3		6.5	9.9	10.7	24.7	26.9	46.4	31.0	55.8	34.0								
F											1	1	3	4	7	4	11		32	1.4	0.9-2.0	95.2	0.1	748	2.9 (1.9-3.9)	
											1.6	2.2	8.2	13.5	27.1	20.3	59.0									
Stomach (C160-C169)																										
M								2	1	4	3	5	8	6	11	20	13	10	83	4.9	3.8-6.0	502.8	0.5	216	9.4 (7.3-11.4)	
								2.5	1.3	5.2	4.2	7.6	16.5	16.2	39.2	88.6	90.7	113.4								
F									1	2	2	5	2	2	5	8	6	8	43	2.2	1.5-2.9	330.0	0.2	454	4 (2.8-5.1)	
								2.6	1.3	2.6	2.9	8.0	4.4	5.4	16.9	31.0	30.4	42.9								
Small intestine (C170-C179)																										
M											1	1	2	2					6	0.4	0.1-0.8	46.2	0.1	1242	0.6 (0.1-1.1)	
											1.5	2.1	5.4	7.1												
F										1		3	1	1			1		8	0.5	0.1-0.9	61.7	0.1	1331	0.8 (0.2-1.3)	
										1.3		2.2	8.2	3.4	3.9		5.4									

Appendix 3B. Cancer mortality, Western Australia, 2006

Age	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+	Total	ASR	95% c.i.	PYLL	CumInc	Risk	ASR2	
Lung, bronchus & trachea (C330-C349)																										
M						1		1	3	8	22	34	57	54	76	75	83	44	458	27.9	25.2-30.5	2602.0	3.2	32	50.5 (45.8-55.2)	
						1.4		1.3	3.8	10.4	31.1	51.9	117.2	145.5	271.1	332.2	579.2	499.1								
F									3	2	15	19	26	34	35	58	40	30	262	14.2	12.3-16.0	1421.3	1.6	62	24.7 (21.7-27.7)	
									3.9	2.6	21.5	30.4	56.6	92.5	118.2	224.8	202.7	161.0								
Thymus (C370-C379)																										
M									1										1	0.1	0 - 0.2	30.0	0.0	*	0.1 (0 - 0.3)	
									1.3																	
F																			0					-		
Pleura, heart & mediastinum (C380-C389)																										
M													1						1	0.1	0 - 0.2	11.5	0.0	9726	0.1 (0 - 0.3)	
													2.1													
F																			0					-		
Bones, joints & articular cartilages (C400-C419)																										
M										1			1	1					3	0.2	0 - 0.5	43.7	0.0	3302	0.3 (0 - 0.6)	
									1.3				2.1	2.7												
F				1											1			2	4	0.2	0 - 0.5	57.5	0.0	4178	0.4 (0.0-0.7)	
				1.4											3.4			10.7								
Skin (melanoma only) (C430-C439)																										
M						1	1	1	7	3	7	6	7	6	10	14	13	7	83	5.1	4.0-6.3	791.9	0.5	196	9 (7.1-11.0)	
						1.4	1.4	1.3	8.9	3.9	9.9	9.2	14.4	16.2	35.7	62.0	90.7	79.4								
F						1		1	1	2	4	6	3	3	8	6	8	2	45	2.6	1.8-3.5	425.5	0.3	314	4.3 (3.0-5.5)	
						1.5		1.3	1.3	2.6	5.7	9.6	6.5	8.2	27.0	23.3	40.5	10.7								
Skin (non-melanoma; includes SCC-BCC) (C440-C449)																										
M									1				3	2	4	5	4	7	38	2.2	1.5-2.9	140.8	0.2	519	4.6 (3.1-6.1)	
									1.3				4.6	4.1	10.8	17.8	17.7	48.8	136.1							
F																3	2	8	13	0.4	0.2-0.6	0.0	0.0	*	1.1 (0.5-1.7)	
																11.6	10.1	42.9								
Mesothelioma (M905; ICD10 C45)																										
M									1		1	3	7	8	10	12	7	9	58	3.6	2.6-4.5	258.7	0.4	254	6.6 (4.9-8.4)	
									1.3		1.4	4.6	14.4	21.6	35.7	53.1	48.8	102.1								
F									1	1				4	2	2	1	2	14	0.9	0.4-1.4	123.5	0.1	851	1.3 (0.6-2.0)	
									1.3	1.3			8.7	5.4	6.8	3.9	10.1	5.4								
Kaposi sarcoma (M914; ICD10 C46)																										
M																			0					-		
F																			0					-		
Nervous system, peripheral/autonomic (C470-C479)																										
M						1								1					2	0.2	0 - 0.4	56.3	0.0	5014	0.2 (0 - 0.4)	
						1.3								2.7												
F																			0					-		

Appendix 3B. Cancer mortality, Western Australia, 2006

Age	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+	Total	ASR	95% c.i.	PYLL	CumInc	Risk	ASR2													
Other male genital (C630-C639)																																						
M																			0																			
Kidney (C640-C649)																																						
M																			41	2.4	1.6-3.1	263.0	0.2	499	4.8 (3.3-6.3)													
F																			19	1.1	0.6-1.6	137.6	0.1	711	1.8 (1.0-2.6)													
Bladder & urinary tract (C650-C689)																																						
M																			76	4.3	3.3-5.3	205.5	0.3	298	9.4 (7.2-11.5)													
F																			31	1.0	0.7-1.4	19.0	0.0	4017	2.7 (1.8-3.7)													
Eye & lacrimal gland (C690-C699)																																						
M																			2	0.1	0 - 0.2	0.0	0.0	*	0.2 (0 - 0.6)													
F																			2	0.1	0 - 0.3	2.4	0.0	5923	0.2 (0 - 0.5)													
Meninges (cerebral & spinal) (C700-C709)																																						
M																			1	0.1	0 - 0.2	11.5	0.0	9726	0.1 (0 - 0.3)													
F																			1	0.1	0 - 0.2	7.1	0.0	7355	0.1 (0 - 0.3)													
Brain (C710-C719)																																						
M																			60	4.3	3.2-5.4	802.9	0.5	191	5.9 (4.4-7.4)													
F																			38	2.7	1.7-3.6	622.2	0.3	330	3.5 (2.4-4.7)													
Spinal cord & cranial nerves (C720-C729)																																						
M																			1	0.1	0 - 0.2	2.4	0.0	5607	0.1 (0 - 0.3)													
F																			0																			
Thyroid gland (C730-C739)																																						
M																			5	0.3	0.0-0.6	59.6	0.0	2795	0.5 (0.1-0.9)													
F																			6	0.3	0.0-0.6	42.7	0.0	2043	0.6 (0.1-1.0)													
Adrenal gland (C740-C749)																																						
M																			3	0.3	0 - 0.6	90.9	0.0	4155	0.3 (0 - 0.6)													
F																			5	0.5	0.0-0.9	184.4	0.0	2882	0.5 (0.1-0.9)													
Endocrine glands (not adrenal) (C750-C759)																																						
M																			1	0.0	0 - 0.1	0.0	0.0	*	0.1 (0 - 0.4)													
F																			0																			

Appendix 3B. Cancer mortality, Western Australia, 2006

Age	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+	Total	ASR	95% c.i.	PYLL	CumInc	Risk	ASR2	
LYMPHOMAS																										
Lymphoma, NOS / unclassifiable																										
M																1	2	1	4	0.2	0 - 0.3	0.0	0.0	*	0.5 (0.0-1.0)	
																4.4	14.0	11.3								
F																	1		1	0.0	0 - 0.1	0.0	0.0	*	0.1 (0 - 0.3)	
																	5.1									
Hodgkin lymphoma																										
M																2		1	3	0.1	0 - 0.3	0.0	0.0	*	0.4 (0 - 0.8)	
																8.9		11.3								
F																			0					-		
All NHL																										
M					1				2		1	7	6	12	7	8	4	8	56	3.7	2.7-4.7	411.5	0.4	234	6.1 (4.4-7.7)	
					1.3				2.5		1.4	10.7	12.3	32.3	25.0	35.4	27.9	90.7								
F					1	2	1		1	1	2	3	3	4	3	9	8	18	56	2.7	1.9-3.6	403.5	0.2	460	5 (3.7-6.3)	
					1.4	3.0	1.4		1.3	1.3	2.9	4.8	6.5	10.9	10.1	34.9	40.5	96.6								
NHL, mature B cell																										
M					1				1		1	7	5	9	6	3	3	4	40	2.7	1.8-3.6	346.7	0.4	284	4.2 (2.8-5.5)	
					1.3				1.3		1.4	10.7	10.3	24.3	21.4	13.3	20.9	45.4								
F					1	1	1		1		2	3	3	3	1	6	6	12	40	2.0	1.3-2.7	319.7	0.2	640	3.5 (2.4-4.6)	
					1.4	1.5	1.4		1.3		2.9	4.8	6.5	8.2	3.4	23.3	30.4	64.4								
NHL, mature T/NK cell																										
M									1			1	1	1	1				5	0.4	0.0-0.7	50.8	0.0	2087	0.5 (0.1-1.0)	
									1.3			2.1	2.7	3.6	4.4											
F										1				1	2	1	1		6	0.4	0.1-0.7	38.0	0.1	1854	0.6 (0.1-1.1)	
										1.3				2.7	6.8	3.9	5.1									
NHL, precursor cell lymphoblastic																										
M																			0					-		
F																			1	0.1	0 - 0.4	45.7	0.0	*	0.1 (0 - 0.3)	
NHL, other/unclassifiable																										
M														2		4	1	4	11	0.6	0.2-1.0	13.9	0.0	3712	1.4 (0.6-2.2)	
														5.4		17.7	7.0	45.4								
F																2	1	6	9	0.3	0.1-0.4	0.0	0.0	*	0.7 (0.2-1.2)	
																7.8	5.1	32.2								
Lymphomas (all)																										
M					1				2		1	7	6	12	7	11	6	10	63	4.0	3.0-5.0	411.5	0.4	234	7 (5.2-8.7)	
					1.3				2.5		1.4	10.7	12.3	32.3	25.0	48.7	41.9	113.4								
F					1	2	1		1	1	2	3	3	4	3	9	9	18	57	2.8	1.9-3.6	403.5	0.2	460	5.1 (3.7-6.4)	
					1.4	3.0	1.4		1.3	1.3	2.9	4.8	6.5	10.9	10.1	34.9	45.6	96.6								
MYELOMA																										
Myeloma/plasma cell tumours																										
M											1	1	5	4	6	9	6	7	39	2.3	1.5-3.0	136.2	0.2	441	4.6 (3.1-6.0)	
											1.4	1.5	10.3	10.8	21.4	39.9	41.9	79.4								
F											1	6	1		1	5	5	4	23	1.0	0.6-1.5	135.1	0.1	1205	2 (1.2-2.9)	
											1.4	9.6	2.2		3.4	19.4	25.3	21.5								

Appendix 3B. Cancer mortality, Western Australia, 2006

Age	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+	Total	ASR	95% c.i.	PYLL	CumInc	Risk	ASR2	
LEUKAEMIAS																										
Leukaemias, NOS/unclassifiable																										
M											1						3	1	5	0.2	0.0-0.4	20.6	0.0	*	0.6 (0.1-1.1)	
											1.4						20.9	11.3								
F																		1	1	0.0	0 - 0.1	0.0	0.0	*	0.1 (0 - 0.2)	
																		5.4								
Leukaemias, lymphoid, all																										
M					1		1		1		1	3	1	4	3	6	4	1	26	1.6	1.0-2.2	234.1	0.2	599	2.8 (1.7-3.9)	
					1.3		1.4		1.3		1.4	4.6	2.1	10.8	10.7	26.6	27.9	11.3								
F						2			1				2	3		4	3	3	18	1.0	0.5-1.6	162.6	0.1	1191	1.7 (0.9-2.4)	
						3.0			1.3				4.4	8.2		15.5	15.2	16.1								
Leukaemias, lymphoid, acute																										
M					1		1				1	1							4	0.3	0.0-0.6	125.6	0.0	3584	0.4 (0.0-0.7)	
					1.3		1.4				1.4	1.5														
F						2			1				1	1		1			6	0.5	0.1-1.0	136.4	0.0	2180	0.6 (0.1-1.1)	
						3.0			1.3				2.2	2.7		3.9										
Leukaemias, lymphoid, chronic																										
M								1			1			3	3	4	3	1	16	0.9	0.5-1.4	74.0	0.1	927	1.8 (0.9-2.7)	
								1.3			1.5			8.1	10.7	17.7	20.9	11.3								
F													1	1		3	2	3	10	0.4	0.1-0.7	19.0	0.0	4084	0.9 (0.3-1.4)	
													2.2	2.7		11.6	10.1	16.1								
Leukaemias, lymphoid, other/NOS																										
M											1	1	1			2	1		6	0.3	0.1-0.6	34.5	0.0	3187	0.6 (0.1-1.1)	
											1.5	2.1	2.7			8.9	7.0									
F													1				1		2	0.1	0 - 0.3	7.1	0.0	7355	0.2 (0 - 0.4)	
													2.7				5.1									
Leukaemias, myeloid, all																										
M						1	1	1	1	1	2	3	7	3	7	8	5	6	46	2.9	2.1-3.8	381.6	0.3	326	5.1 (3.6-6.6)	
						1.4	1.4	1.3	1.3	1.3	2.8	4.6	14.4	8.1	25.0	35.4	34.9	68.1								
F					1		1	1	1	4	1	2	2	1	2		4	4	22	1.3	0.7-1.9	290.5	0.1	753	2 (1.2-2.8)	
					1.4		1.4	1.3		1.3	5.7	1.6	4.4	2.7	6.8		20.3	21.5								
Leukaemias, myeloid, acute																										
M							1	1		1	2	5	3	5	6	3	3	30	1.9	1.2-2.6	207.7	0.2	463	3.3 (2.1-4.5)		
							1.3	1.3		1.4	3.1	10.3	8.1	17.8	26.6	20.9	34.0									
F					1		1		1	4	1	2	2	1	1		4	3	19	1.1	0.6-1.7	252.4	0.1	914	1.7 (0.9-2.5)	
					1.4		1.4		1.3	5.7	1.6	4.4	2.7	3.4		20.3	16.1									
Leukaemias, myeloid, chronic																										
M						1	1		1	1	1			1	2		1		9	0.6	0.2-1.0	148.4	0.1	1892	1 (0.3-1.6)	
						1.4	1.4		1.3	1.4	1.5			3.6	8.9		11.3									
F								1											1	0.1	0 - 0.2	35.7	0.0	*	0.1 (0 - 0.3)	
								1.3																		
Leukaemias, myeloid, other/NOS																										
M													2		1		2	2	7	0.4	0.1-0.7	25.3	0.0	2605	0.8 (0.2-1.5)	
													4.1		3.6		14.0	22.7								
F															1			1	2	0.1	0 - 0.2	2.4	0.0	5923	0.2 (0 - 0.4)	
															3.4			5.4								

Appendix 3B. Cancer mortality, Western Australia, 2006

Age	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+	Total	ASR	95% c.i.	PYLL	CumInc	Risk	ASR2	
Leukaemias, other																										
M																				0					-	
F																				0					-	
Leukaemias (all)																										
M					1	1	2	1	2	1	4	6	8	7	10	14	12	8	77	4.8	3.7-5.9	636.7	0.5	208	8.5 (6.6-10.4)	
					1.3	1.4	2.7	1.3	2.5	1.3	5.6	9.2	16.5	18.9	35.7	62.0	83.7	90.7								
F					1	2	1	1		2	4	1	4	4	2	4	7	8	41	2.4	1.6-3.2	453.2	0.2	462	3.7 (2.6-4.9)	
					1.4	3.0	1.4	1.3		2.6	5.7	1.6	8.7	10.9	6.8	15.5	35.5	42.9								
MYELOYDYSPLASTIC DISEASES																										
Refractory anaemias/cytopaenias																										
M														2	2	2		4	10	0.6	0.2-1.0	18.7	0.1	1597	1.3 (0.5-2.1)	
														5.4	7.1	8.9		45.4								
F													1	2	2	1	2	6	14	0.6	0.3-1.0	31.0	0.1	1392	1.2 (0.6-1.9)	
													2.2	5.4	6.8	3.9	10.1	32.2								
Myelodysplastic syndromes																										
M											1	1	4	4	5	7	11	33	1.8	1.2-2.5	64.9	0.1	699	4.1 (2.7-5.6)		
											1.5	2.1	10.8	14.3	22.1	48.8	124.8									
F		1									1	2	2	1	1		9	17	0.9	0.4-1.5	129.2	0.1	1223	1.4 (0.7-2.1)		
		1.6									1.6	4.4	5.4	3.4	3.9		48.3									
Myelodysplastic diseases, all																										
M											1	1	6	6	7	7	15	43	2.5	1.7-3.2	83.5	0.2	486	5.4 (3.8-7.1)		
											1.5	2.1	16.2	21.4	31.0	48.8	170.1									
F		1									1	3	4	3	2	2	15	31	1.6	0.9-2.2	160.2	0.2	651	2.7 (1.7-3.6)		
		1.6									1.6	6.5	10.9	10.1	7.8	10.1	80.5									
CHRONIC MYELOPROLIFERATIVE DISEASES																										
Chronic myeloproliferative disorder, NOS																										
M													1		2	1	1	5	0.3	0.0-0.6	16.2	0.0	2177	0.6 (0.1-1.1)		
													2.1		7.1	4.4	11.3									
F																1	1	2	0.1	0 - 0.1	0.0	0.0	*	0.2 (0 - 0.4)		
																5.1	5.4									
Polycythaemia rubra vera																										
M														1	1		2	4	0.2	0 - 0.5	9.3	0.0	3194	0.4 (0.0-0.9)		
														2.7	3.6		14.0									
F																1		1	0.0	0 - 0.1	0.0	0.0	*	0.1 (0 - 0.3)		
																3.9										
Myelofibrosis/sclerosis																										
M												1	1			3	2	7	0.4	0.1-0.7	27.5	0.0	5585	0.8 (0.2-1.5)		
												1.5	2.1			13.3	22.7									
F																1	1	2	0.1	0 - 0.1	0.0	0.0	*	0.2 (0 - 0.4)		
																5.1	5.4									
Other chronic myeloproliferative d/o																										
M																			0					-		
F																	1	1	2	0.1	0 - 0.1	0.0	0.0	*	0.2 (0 - 0.4)	
																5.1	5.4									

Appendix 3B. Cancer mortality, Western Australia, 2006

Age	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85 +	Total	ASR	95% c.i.	PYLL	CumInc	Risk	ASR2		
Chronic myeloproliferative d/o, all																											
M												1	2	1	3	4	2	3	16	0.9	0.5-1.4	53.1	0.1	1051	1.9 (0.9-2.8)		
												1.5	4.1	2.7	10.7	17.7	14.0	34.0									
F																1	3	3	7	0.2	0.0-0.3	0.0	0.0	*	0.6 (0.1-1.0)		
																3.9	15.2	16.1									
OTHER CHRONIC IMMUNOPROLIFERATIVE DISEASES																											
Mast cell tumours																											
M																			0					-			
F													1						1	0.1	0 - 0.3	11.9	0.0	9181	0.1 (0 - 0.3)		
													2.2														
Histiocytic/dendritic cell malignancies																											
M																			0					-			
F																			0					-			
Other & U/S immunoproliferative neoplasms																											
M																	1	1	2	0.1	0 - 0.2	0.0	0.0	*	0.3 (0 - 0.7)		
																	7.0	11.3									
F																			0					-			
Other chronic immunoproliferative d/o, all																											
M																	1	1	2	0.1	0 - 0.2	0.0	0.0	*	0.3 (0 - 0.7)		
																	7.0	11.3									
F													1						1	0.1	0 - 0.3	11.9	0.0	9181	0.1 (0 - 0.3)		
													2.2														
Unknown primary site (C80 or Behaviour 6/9)																											
M									3	2	5	8	6	5	14	18	19		80	4.5	3.5-5.5	342.9	0.3	309	9.4 (7.3-11.6)		
									3.9	2.8	7.6	16.5	16.2	17.8	62.0	125.6	215.5										
F								2	2	3	6	2	10	7	14	17	29		92	4.1	3.2-5.1	399.2	0.4	269	8.1 (6.5-9.8)		
								2.6	2.6	4.3	9.6	4.4	27.2	23.6	54.3	86.1	155.6										
Total deaths due to cancer																											
M	1	1		4	6	8	11	32	51	82	153	205	224	279	365	350	275		2047	123.3	118-129	12661.6	12.6	8	229.9 (220-240)		
	1.5	1.3		5.2	8.5	10.8	14.0	40.6	66.6	115.8	233.3	421.6	603.6	995.3	1616.5	2442.3	3119.3										
F	3	2	1	1	2	6	11	18	36	51	76	134	130	154	168	231	279		1523	82.5	77.9-87.0	11523.8	8.8	12	139.9 (133-147)		
	4.7	3.0	1.4	1.4	2.8	8.9	15.2	23.6	46.3	67.1	109.0	214.6	283.2	418.8	567.4	895.4	1114.6	1497.2									

Appendix 3C. Childhood cancer, Western Australia, 2006 (WHO International Classification, version 3)

	Males								Females								All							
	Age Group				Total	ASR	95%c.i.	TD%	Age Group				Total	ASR	95%c.i.	TD%	Age Group				Total	ASR	95%c.i.	TD%
	0	1-4	5-9	10-14					0	1-4	5-9	10-14					0	1-4	5-9	10-14				
I. LEUKAEMIAS, MYELOPROLIFERATIVE AND MYELODYSPLASTIC DISEASES																								
All	2	3	3		8	3.9	1.1-6.6	100	2	1			3	1.8	0 - 3.8	100	4	4	3		11	2.8	1.1-4.5	100
	4.0	4.4	4.1						4.1	1.6							4.1	3.0	2.1					
Lymphoid leukaemia	1	3	1		5	2.4	0.3-4.6	100	2	1			3	1.8	0 - 3.8	100	3	4	1		8	2.1	0.6-3.6	100
	2.0	4.4	1.4						4.1	1.6							3.0	3.0	0.7					
Acute myeloid leukaemia	1		2		3	1.4	0 - 3.1	100					0				1		2		3	0.7	0 - 1.6	100
	2.0		2.7														1.0		1.4					
Chronic MPDs					0								0								0			
MDS & other MPDs					0								0								0			
Unspecified/other leukaemia					0								0								0			
II. LYMPHOMAS																								
All		2	3		5	2.1	0.3-4.0	100			2		2	0.8	0 - 2.0	100		2	5		7	1.5	0.4-2.6	100
		2.9	4.1								2.9							1.5	3.5					
Hodgkin lymphoma			2		2	0.8	0 - 1.9	100			2		2	0.8	0 - 2.0	100			4		4	0.8	0.0-1.6	100
			2.7								2.9								2.8					
Non-Hodgkin lymphoma exc Burkitt	1	1			2	0.9	0 - 2.1	100					0					1	1		2	0.4	0 - 1.1	100
	1.5	1.4																0.8	0.7					
Burkitt lymphoma	1				1	0.5	0 - 1.4	100					0					1			1	0.2	0 - 0.7	100
	1.5																	0.8						
Misc. lymphoreticular neoplasms					0								0								0			
Unspecified lymphoma					0								0								0			
III. CNS AND INTRACRANIAL/SPINAL																								
All	6	1			7	3.2	0.8-5.6	100	2	3	1		6	3.2	0.6-5.8	50	2	9	2		13	3.2	1.5-5.0	77
	8.8	1.4							4.1	4.7	1.4						2.0	6.8	1.4					
Ependymoma/choroid plexus	1	1			2	0.9	0 - 2.1	100					0					1	1		2	0.4	0 - 1.1	100
	1.5	1.4																0.8	0.7					
Astrocytoma	2				2	0.9	0 - 2.3	100	1		1		2	1.1	0 - 2.6	50	1	2	1		4	1.0	0.0-2.0	75
	2.9								2.1		1.4						1.0	1.5	0.7					
Embryonal tumours	1				1	0.5	0 - 1.4	100	1	1			2	1.1	0 - 2.7	100	1	2			3	0.8	0 - 1.7	100
	1.5								2.1	1.6							1.0	1.5						
Other gliomas					0					1			1	0.5	0 - 1.5	0		1			1	0.2	0 - 0.7	0
										1.6								0.8						
Other intracranial/spinal		2			2	0.9	0 - 2.3	100					0					2			2	0.5	0 - 1.2	100
		2.9																1.5						
Unspecified					0					1			1	0.5	0 - 1.5	0		1			1	0.2	0 - 0.7	0
										1.6								0.8						

Appendix 3C. Childhood cancer, Western Australia, 2006 (WHO International Classification, version 3)

	Males					Females					All													
	Age Group				Total	ASR	95%c.i.	TD%	Age Group				Total	ASR	95%c.i.	TD%								
	0	1-4	5-9	10-14					0	1-4	5-9	10-14					0	1-4	5-9	10-14				
IV. NEUROBLASTOMA & PERIPHERAL NERVOUS SYSTEM TUMOURS																								
All	1				1	0.6	0 - 1.9	100	1	2			3	1.9	0 - 4.1	100	2	2			4	1.3	0.0-2.5	100
	8.3								8.4	4.1							8.4	2.0						
Neuroblastoma/ganglioneuobl.	1				1	0.6	0 - 1.9	100	1	2			3	1.9	0 - 4.1	100	2	2			4	1.3	0.0-2.5	100
	8.3								8.4	4.1							8.4	2.0						
Other					0								0								0			
V. RETINOBLASTOMA																								
All	1				1	0.6	0 - 1.9	0					0				1				1	0.3	0 - 1.0	0
	8.3																4.2							
VI. RENAL TUMOURS																								
All					0					1			1	0.5	0 - 1.5	100		1			1	0.2	0 - 0.7	100
										1.6								0.8						
Nephroblastoma/oth non-epithel.					0					1			1	0.5	0 - 1.5	100		1			1	0.2	0 - 0.7	100
										1.6								0.8						
Renal carcinoma					0								0								0			
Unspecified					0								0								0			
VII. HEPATIC TUMOURS																								
All					0								0								0			
Hepatoblastoma					0								0								0			
Hepatic carcinoma					0								0								0			
Unspecified					0								0								0			
VIII. BONE																								
All			1		1	0.4	0 - 1.2	100		1			1	0.6	0 - 1.9	0	1	1			2	0.5	0 - 1.3	50
			1.4							2.1							1.0	0.7						
Osteosarcoma					0								0								0			
Chondrosarcoma					0								0								0			
Ewing & related sarcoma			1		1	0.4	0 - 1.2	100		1			1	0.6	0 - 1.9	0	1	1			2	0.5	0 - 1.3	50
			1.4							2.1							1.0	0.7						
Other specified					0								0								0			
Unspecified					0								0								0			

Appendix 3C. Childhood cancer, Western Australia, 2006 (WHO International Classification, version 3)

	Males				Total	ASR	95%c.i.	TD%	Females				Total	ASR	95%c.i.	TD%	All				Total	ASR	95%c.i.	TD%
	Age Group								Age Group								Age Group							
	0	1-4	5-9	10-14					0	1-4	5-9	10-14					0	1-4	5-9	10-14				
IX. SOFT TISSUE SARCOMA																								
All	1		1		2	1.0	0 - 2.5	100	1		2		3	1.5	0 - 3.2	100	1	1		3	5	1.3	0.1-2.4	100
	2.0		1.4						8.4		2.9						4.2	1.0		2.1				
Rhabdomyosarcoma	1				1	0.6	0 - 1.8	100	1		1		2	1.1	0 - 2.6	100	1	1		1	3	0.8	0 - 1.8	100
	2.0								8.4		1.4						4.2	1.0		0.7				
Fibrosarcoma/Neurofibrosarc.					0						1		1	0.4	0 - 1.2	100				1	1	0.2	0 - 0.6	100
											1.4									0.7				
Kaposi sarcoma					0								0								0			
Other specified				1	1	0.4	0 - 1.2	100					0							1	1	0.2	0 - 0.6	100
				1.4																0.7				
Unspecified					0								0								0			
X. GONADAL AND GERM CELL																								
All		2		1	3	1.6	0 - 3.5	100					0					2		1	3	0.8	0 - 1.8	100
		4.0		1.4														2.0		0.7				
Intracranial/spinal				1	1	0.4	0 - 1.2	100					0							1	1	0.2	0 - 0.6	100
				1.4																0.7				
Other/unspecified non-gonadal					0								0								0			
Gonadal germ cell		2			2	1.2	0 - 2.9	100					0					2			2	0.6	0 - 1.5	100
		4.0																2.0						
Gonadal carcinoma					0								0								0			
Other and unspecified					0								0								0			
XI. OTHER EPITHELIAL / MELANOMA																								
All				1	1	0.4	0 - 1.2	100			2		2	0.8	0 - 2.0	100				3	3	0.6	0 - 1.3	100
				1.4							2.9									2.1				
Adrenocortical carcinoma					0								0								0			
Thyroid carcinoma					0						1		1	0.4	0 - 1.2	100				1	1	0.2	0 - 0.6	100
											1.4									0.7				
Nasopharyngeal carcinoma					0								0								0			
Malignant melanoma					0								0								0			
Skin carcinomas					0								0								0			
Other/unspecified carcinoma				1	1	0.4	0 - 1.2	100			1		1	0.4	0 - 1.2	100				2	2	0.4	0 - 1.0	100
				1.4							1.4									1.4				

Appendix 3C. Childhood cancer, Western Australia, 2006 (WHO International Classification, version 3)

	Males				Total	ASR	95%c.i.	TD%	Females				Total	ASR	95%c.i.	TD%	All				Total	ASR	95%c.i.	TD%			
	Age Group								Age Group								Age Group										
	0	1-4	5-9	10-14					0	1-4	5-9	10-14					0	1-4	5-9	10-14							
XII. OTHER																											
All					0								0									0					
Other specified malignancy					0								0									0					
Other unspecified malignancy					0								0									0					
Total					29	14.0	8.8-19.1	97	2	7	5	7	21	11.2	6.3-16.1	81	4	12	16	18	50	12.6	9.1-16.2	90			
	2	5	11	11					2	7	5	7					4	12	16	18							
	16.6	9.9	16.2	15.1					16.9	14.5	7.8	10.1					16.8	12.2	12.1	12.7							

Appendix 3D. Cancer incidence, Western Australia, 2006: Leading types by sex and geographic area

CHS Kimberley Region

Males						Females					
	Cases	%	ASR	95%c.i.	Risk		Cases	%	ASR	95%c.i.	Risk
Prostate	10	17.9	64.7	23.5-106	10	Breast	8	19.5	62.1	16.6-108	13
Melanoma (skin)	6	10.7	31.4	5.3-57.5	23	Lung	6	14.6	41.2	7.6-74.8	28
Lung	5	8.9	33.8	3.5-64.0	24	Melanoma (skin)	5	12.2	29.3	3.6-55.0	37
Colorectal	4	7.1	25.1	0 - 50.8	25	Uterus	5	12.2	33.9	2.0-65.9	25
Colon	2	3.6	8.8	0 - 21.1	136	Cervix	3	7.3	15.3	0 - 32.6	74
Rectum	2	3.6	16.3	0 - 38.9	30	Colorectal	2	4.9	14.4	0 - 35.0	64
Pharynx	3	5.4	14.6	0 - 31.2	59	Colon	0		0.0	0 - 0.0	-
Pancreas	3	5.4	14.8	0 - 31.4	61	Rectum	2	4.9	14.4	0 - 35.0	64
Larynx	3	5.4	14.6	0 - 31.2	59	Pancreas	2	4.9	16.9	0 - 42.0	30
Leukaemia	3	5.4	23.7	0 - 50.5	33	Lymphoma	2	4.9	23.9	0 - 56.9	21
Leukaemia NOS	0		0.0	0 - 0.0	-	Lymphoma NOS	0		0.0	0 - 0.0	-
Lymphoid leukaemia	3	5.4	23.7	0 - 50.5	33	Hodgkin lymphoma	0		0.0	0 - 0.0	-
Myeloid leukaemia	0		0.0	0 - 0.0	-	NHL	2	4.9	23.9	0 - 56.9	21
Leukaemia, other	0		0.0	0 - 0.0	-						
All cancers	56	100.0	334.2	244-424	3	All cancers	41	100.0	295.0	200-390	4

CHS Pilbara Region

Males						Females					
	Cases	%	ASR	95%c.i.	Risk		Cases	%	ASR	95%c.i.	Risk
Melanoma (skin)	11	23.4	40.5	15.1-65.9	28	Breast	6	21.4	33.1	4.0-62.1	29
Prostate	8	17.0	41.6	8.4-74.9	18	Colorectal	4	14.3	28.1	0 - 62.3	103
Colorectal	5	10.6	30.1	0 - 64.0	19	Colon	2	7.1	20.5	0 - 53.0	229
Colon	2	4.3	5.6	0 - 13.4	167	Rectum	2	7.1	7.6	0 - 18.2	185
Rectum	3	6.4	24.5	0 - 57.5	21	Melanoma (skin)	4	14.3	27.5	0 - 61.5	106
Lung	5	10.6	28.9	3.0-54.8	28	Lung	2	7.1	22.7	0 - 60.6	20
Stomach	2	4.3	22.4	0 - 59.9	251	Ovary	2	7.1	10.3	0 - 25.5	152
Brain	2	4.3	5.6	0 - 13.3	216	Lymphoma	2	7.1	10.8	0 - 26.4	143
Thyroid gland	2	4.3	6.1	0 - 14.6	156	Lymphoma NOS	0		0.0	0 - 0.0	-
Unknown primary	2	4.3	13.6	0 - 35.1	341	Hodgkin lymphoma	1	3.6	7.1	0 - 20.9	255
Leukaemia	2	4.3	12.9	0 - 33.4	53	NHL	1	3.6	3.7	0 - 10.9	326
Leukaemia NOS	0		0.0	0 - 0.0	-						
Lymphoid leukaemia	1	2.1	10.0	0 - 29.7	60						
Myeloid leukaemia	1	2.1	2.9	0 - 8.6	414						
Leukaemia, other	0		0.0	0 - 0.0	-						
All cancers	47	100.0	251.4	164-338	4	All cancers	28	100.0	189.0	104-274	6

CHS Midwest Region

Males						Females					
	Cases	%	ASR	95%c.i.	Risk		Cases	%	ASR	95%c.i.	Risk
Prostate	40	23.5	87.9	60.3-115	9	Breast	46	35.7	116.9	82.7-151	7
Lung	29	17.1	58.5	36.7-80.2	14	Melanoma (skin)	14	10.9	32.2	15.0-49.5	26
Colorectal	21	12.4	43.5	24.5-62.4	18	Colorectal	12	9.3	28.1	11.8-44.4	29
Colon	11	6.5	23.9	9.6-38.3	30	Colon	8	6.2	17.7	5.0-30.5	49
Rectum	10	5.9	19.5	7.1-31.9	43	Rectum	4	3.1	10.4	0.2-20.6	69
Melanoma (skin)	19	11.2	42.4	23.2-61.6	20	Lung	12	9.3	26.1	10.9-41.3	38
Bladder & urinary tract	6	3.5	12.9	2.4-23.4	61	Thyroid gland	6	4.7	14.4	2.6-26.3	74
Oesophagus	5	2.9	10.9	1.1-20.6	74	Uterus	5	3.9	13.3	1.6-24.9	51
Larynx	5	2.9	9.0	0.9-17.1	87	Unknown primary	5	3.9	8.2	0.7-15.7	464
Unknown primary	5	2.9	9.8	1.1-18.5	60	Pancreas	4	3.1	9.1	0.0-18.2	61
Lymphoma	5	2.9	9.6	0.9-18.2	124	Kidney	3	2.3	7.4	0 - 15.8	91
Lymphoma NOS	0		0.0	0 - 0.0	-	Lymphoma	3	2.3	10.2	0 - 22.2	105
Hodgkin lymphoma	0		0.0	0 - 0.0	-	Lymphoma NOS	0		0.0	0 - 0.0	-
NHL	5	2.9	9.6	0.9-18.2	124	Hodgkin lymphoma	1	0.8	4.7	0 - 13.9	385
						NHL	2	1.6	5.5	0 - 13.2	145
All cancers	170	100.0	358.2	304-413	3	All cancers	129	100.0	313.2	258-369	3

Appendix 3D. Cancer incidence, Western Australia, 2006: Leading types by sex and geographic area

CHS Wheatbelt Region

Males						Females					
	Cases	%	ASR	95%c.i.	Risk		Cases	%	ASR	95%c.i.	Risk
Prostate	74	33.0	106.3	81.8-131	8	Breast	48	31.0	87.7	62.2-113	11
Colorectal	25	11.2	36.8	22.2-51.4	26	Colorectal	20	12.9	30.5	16.3-44.7	29
Colon	13	5.8	18.5	8.3-28.8	64	Colon	15	9.7	23.4	10.8-36.1	35
Rectum	12	5.4	18.3	7.8-28.7	44	Rectum	5	3.2	7.0	0.4-13.6	157
Lung	25	11.2	35.1	21.1-49.1	22	Melanoma (skin)	12	7.7	22.8	9.5-36.2	37
Melanoma (skin)	24	10.7	42.2	24.3-60.0	22	Uterus	11	7.1	16.9	6.4-27.5	61
Unknown primary	10	4.5	21.0	6.2-35.9	53	Lung	8	5.2	12.7	3.5-21.9	63
Lymphoma	8	3.6	14.2	4.1-24.3	70	Lymphoma	8	5.2	13.1	3.4-22.8	84
Lymphoma NOS	0		0.0	0 - 0.0	-	Lymphoma NOS	0		0.0	0 - 0.0	-
Hodgkin lymphoma	0		0.0	0 - 0.0	-	Hodgkin lymphoma	1	0.6	2.3	0 - 6.7	529
NHL	8	3.6	14.2	4.1-24.3	70	NHL	7	4.5	10.9	2.3-19.5	100
Lip, gum & mouth	7	3.1	10.7	2.6-18.8	85	Lip, gum & mouth	6	3.9	12.0	1.8-22.3	56
Oesophagus	7	3.1	10.8	2.7-19.0	77	Unknown primary	6	3.9	9.7	1.3-18.1	95
Kidney	6	2.7	11.2	2.2-20.2	76	Leukaemia	6	3.9	8.9	1.3-16.4	79
Pancreas	5	2.2	8.1	1.0-15.1	93	Leukaemia NOS	0		0.0	0 - 0.0	-
Leukaemia	4	1.8	6.0	0.0-11.9	142	Lymphoid leukaemia	5	3.2	8.1	0.7-15.5	79
						Myeloid leukaemia	1	0.6	0.8	0 - 2.3	*
All cancers	224	100.0	355.8	307-405	3	All cancers	155	100.0	265.7	222-310	4

CHS Goldfields Region

Males						Females					
	Cases	%	ASR	95%c.i.	Risk		Cases	%	ASR	95%c.i.	Risk
Prostate	26	25.5	88.5	54.0-123	10	Breast	18	29.5	60.4	32.1-88.7	15
Colorectal	18	17.6	57.3	30.3-84.3	12	Melanoma (skin)	14	23.0	50.5	23.6-77.5	20
Colon	10	9.8	32.3	11.9-52.6	23	Colorectal	4	6.6	14.4	0.0-28.8	66
Rectum	8	7.8	25.0	7.2-42.8	25	Colon	3	4.9	9.6	0 - 20.5	107
Lung	11	10.8	36.9	14.8-59.1	19	Rectum	1	1.6	4.8	0 - 14.2	168
Melanoma (skin)	9	8.8	27.2	9.1-45.3	32	Uterus	4	6.6	11.3	0.1-22.4	242
Lip, gum & mouth	4	3.9	12.9	0 - 25.8	325	Ovary	3	4.9	12.3	0 - 26.6	52
Unknown primary	4	3.9	12.7	0.1-25.4	105	Leukaemia	3	4.9	12.7	0 - 27.9	199
Lymphoma	4	3.9	13.5	0.0-27.0	51	Leukaemia NOS	0		0.0	0 - 0.0	-
Lymphoma NOS	0		0.0	0 - 0.0	-	Lymphoid leukaemia	1	1.6	5.6	0 - 16.4	433
Hodgkin lymphoma	0		0.0	0 - 0.0	-	Myeloid leukaemia	2	3.3	7.1	0 - 17.7	369
NHL	4	3.9	13.5	0.0-27.0	51	Leukaemia, other	0		0.0	0 - 0.0	-
Pancreas	3	2.9	11.0	0 - 23.4	66	Gallbladder / bile ducts	2	3.3	6.3	0 - 15.2	354
						Lung	2	3.3	7.2	0 - 17.8	122
						Kidney	2	3.3	8.2	0 - 19.9	81
						Lymphoma	2	3.3	5.2	0 - 12.4	413
All cancers	102	100.0	335.4	270-401	3	All cancers	61	100.0	213.6	159-269	5

CHS Great Southern Region

Males						Females					
	Cases	%	ASR	95%c.i.	Risk		Cases	%	ASR	95%c.i.	Risk
Prostate	47	29.7	92.8	65.3-120	8	Breast	55	40.1	138.9	99.9-178	7
Colorectal	22	13.9	44.9	25.5-64.4	19	Colorectal	17	12.4	30.0	14.4-45.7	30
Colon	8	5.1	14.6	4.0-25.3	71	Colon	16	11.7	27.2	12.5-41.9	33
Rectum	14	8.9	30.3	14.0-46.6	25	Rectum	1	0.7	2.8	0 - 8.3	429
Melanoma (skin)	19	12.0	48.2	25.2-71.2	24	Lung	14	10.2	24.5	10.6-38.4	30
Lung	18	11.4	35.3	18.1-52.4	26	Melanoma (skin)	11	8.0	29.7	10.6-48.9	36
Stomach	8	5.1	15.0	4.2-25.8	62	Lymphoma	8	5.8	20.8	3.4-38.2	52
Lip, gum & mouth	5	3.2	11.9	1.2-22.6	84	Lymphoma NOS	0		0.0	0 - 0.0	-
Skin (NMSC exc. SCC/BCC)	4	2.5	5.6	0 - 11.6	254	Hodgkin lymphoma	3	2.2	14.1	0 - 30.3	113
Kidney	4	2.5	8.4	0 - 16.8	102	NHL	5	3.6	6.7	0.2-13.1	96
Bladder & urinary tract	4	2.5	6.0	0 - 12.3	134	Thyroid gland	5	3.6	14.2	1.5-26.8	64
Unknown primary	4	2.5	7.4	0 - 15.3	213	Uterus	4	2.9	7.6	0 - 15.4	77
Lymphoma	4	2.5	9.2	0.1-18.3	82	Unknown primary	4	2.9	6.7	0 - 13.8	129
Lymphoma NOS	0		0.0	0 - 0.0	-	Stomach	3	2.2	5.6	0 - 12.3	129
Hodgkin lymphoma	0		0.0	0 - 0.0	-	Connective/ soft tissues	2	1.5	8.1	0 - 19.8	189
NHL	4	2.5	9.2	0.1-18.3	82	Ovary	2	1.5	5.0	0 - 12.0	160
Leukaemia	4	2.5	11.3	0 - 25.1	152						
All cancers	158	100.0	343.0	286-400	3	All cancers	137	100.0	309.2	252-366	3

Appendix 3D. Cancer incidence, Western Australia, 2006: Leading types by sex and geographic area

CHS South West Region

Males						Females					
	Cases	%	ASR	95%c.i.	Risk		Cases	%	ASR	95%c.i.	Risk
Prostate	110	28.8	95.7	77.3-114	8	Breast	73	26.4	68.1	51.7-84.5	14
Melanoma (skin)	54	14.1	50.2	36.1-64.2	18	Melanoma (skin)	36	13.0	35.8	23.5-48.1	28
Lung	38	9.9	30.7	20.6-40.8	28	Colorectal	35	12.7	27.3	17.6-37.0	34
Colorectal	35	9.2	34.8	22.5-47.1	23	Colon	23	8.3	17.1	9.5-24.6	47
Colon	23	6.0	23.0	12.7-33.3	38	Rectum	12	4.3	10.2	4.1-16.4	119
Rectum	12	3.1	11.8	5.0-18.6	56	Lung	25	9.1	21.0	12.3-29.7	36
Lymphoma	20	5.2	19.5	10.7-28.4	37	Lymphoma	16	5.8	17.3	8.3-26.3	62
Lymphoma NOS	0		0.0	0 - 0.0	-	Lymphoma NOS	0		0.0	0 - 0.0	-
Hodgkin lymphoma	1	0.3	1.1	0 - 3.2	562	Hodgkin lymphoma	4	1.4	6.1	0 - 12.3	242
NHL	19	5.0	18.5	9.9-27.1	39	NHL	12	4.3	11.3	4.7-17.8	83
Bladder & urinary tract	16	4.2	13.2	6.4-20.0	76	Unknown primary	10	3.6	5.1	1.8-8.4	871
Leukaemia	13	3.4	13.8	6.0-21.5	60	Uterus	9	3.3	7.3	2.3-12.3	102
Leukaemia NOS	0		0.0	0 - 0.0	-	Bladder & urinary tract	8	2.9	6.2	1.5-11.0	137
Lymphoid leukaemia	9	2.4	9.5	3.1-16.0	76	Cervix	7	2.5	10.3	2.3-18.3	131
Myeloid leukaemia	4	1.0	4.2	0 - 8.6	285	Ovary	7	2.5	6.3	1.4-11.3	117
Leukaemia, other	0		0.0	0 - 0.0	-	Thyroid gland	7	2.5	6.7	1.6-11.8	154
Unknown primary	12	3.1	9.4	3.9-14.9	152	Leukaemia	5	1.8	4.2	0.3-8.2	218
Oesophagus	11	2.9	9.3	3.6-14.9	93	Leukaemia NOS	0		0.0	0 - 0.0	-
Lip, gum & mouth	9	2.4	8.5	2.9-14.1	138	Lymphoid leukaemia	5	1.8	4.2	0.3-8.2	218
Pancreas	8	2.1	7.3	2.1-12.5	110	Myeloid leukaemia	0		0.0	0 - 0.0	-
Brain	8	2.1	9.7	2.4-16.9	98	Leukaemia, other	0		0.0	0 - 0.0	-
Kidney	7	1.8	6.4	1.6-11.1	144	Pancreas	4	1.4	2.8	0 - 5.9	487
Stomach	6	1.6	5.6	1.1-10.1	150	Brain	4	1.4	4.5	0 - 9.4	232
Myelodysplastic diseases	5	1.3	4.6	0.5-8.8	182	Myeloma	4	1.4	2.8	0 - 5.7	284
Liver	4	1.0	4.2	0.1-8.3	181	Pharynx	3	1.1	3.2	0 - 6.9	265
Mesothelioma	4	1.0	3.3	0.0-6.7	229	Gallbladder / bile ducts	3	1.1	1.9	0 - 4.2	421
						Skin (NMSC exc. SCC/BCC)	3	1.1	2.7	0 - 5.8	517
						Kidney	3	1.1	2.8	0 - 6.1	418
All cancers	382	100.0	349.6	313-386	3	All cancers	276	100.0	249.9	218-281	4

WA Country - all

Males						Females					
	Cases	%	ASR	95%c.i.	Risk		Cases	%	ASR	95%c.i.	Risk
Prostate	315	27.7	92.9	82.4-103	9	Breast	254	30.7	84.5	73.9-95.2	11
Melanoma (skin)	142	12.5	44.2	36.7-51.6	21	Melanoma (skin)	96	11.6	33.0	26.2-39.9	30
Lung	131	11.5	37.8	31.2-44.5	22	Colorectal	94	11.4	27.8	21.9-33.8	33
Colorectal	130	11.4	39.6	32.6-46.5	20	Colon	67	8.1	19.1	14.3-24.0	45
Colon	69	6.1	20.9	15.8-26.0	42	Rectum	27	3.3	8.7	5.3-12.2	121
Rectum	61	5.4	18.7	13.9-23.4	39	Lung	69	8.3	20.6	15.5-25.7	39
Lymphoma	43	3.8	13.2	9.2-17.2	61	Lymphoma	41	5.0	14.2	9.6-18.9	72
Lymphoma NOS	0		0.0	0 - 0.0	-	Lymphoma NOS	0		0.0	0 - 0.0	-
Hodgkin lymphoma	1	0.1	0.3	0 - 1.0	1739	Hodgkin lymphoma	10	1.2	5.0	1.8-8.2	311
NHL	42	3.7	12.8	8.9-16.8	63	NHL	31	3.7	9.2	5.8-12.6	94
Unknown primary	39	3.4	11.2	7.5-14.8	96	Uterus	38	4.6	11.4	7.7-15.2	73
Bladder & urinary tract	32	2.8	9.1	5.9-12.4	107	Unknown primary	27	3.3	6.4	3.8-9.0	221
Lip, gum & mouth	31	2.7	9.3	6.0-12.6	112	Thyroid gland	24	2.9	7.9	4.6-11.1	122
Leukaemia	31	2.7	10.0	6.3-13.7	88	Ovary	20	2.4	6.8	3.7-9.9	101
Leukaemia NOS	1	0.1	0.2	0 - 0.5	*	Pancreas	16	1.9	4.8	2.4-7.3	154
Lymphoid leukaemia	22	1.9	7.3	4.1-10.5	112	Leukaemia	15	1.8	5.0	2.2-7.9	202
Myeloid leukaemia	8	0.7	2.6	0.7-4.4	397	Leukaemia NOS	0		0.0	0 - 0.0	-
Leukaemia, other	0		0.0	0 - 0.0	-	Lymphoid leukaemia	11	1.3	3.7	1.3-6.2	231
Oesophagus	27	2.4	7.9	4.8-10.9	113	Myeloid leukaemia	4	0.5	1.3	0 - 2.8	1574
Pancreas	24	2.1	7.6	4.5-10.6	97	Leukaemia, other	0		0.0	0 - 0.0	-
Kidney	22	1.9	6.6	3.8-9.4	126	Lip, gum & mouth	13	1.6	4.4	1.9-6.9	157
Stomach	20	1.8	5.6	3.1-8.2	141	Cervix	13	1.6	5.0	2.2-7.9	212
Pharynx	15	1.3	4.4	2.2-6.7	193	Bladder & urinary tract	12	1.5	3.1	1.2-4.9	292
Larynx	14	1.2	4.1	1.9-6.3	196	Kidney	9	1.1	3.0	1.0-5.0	273
Skin (NMSC exc. SCC/BCC)	14	1.2	4.2	1.9-6.4	202	Brain	9	1.1	2.8	0.8-4.8	394
Brain	13	1.1	4.5	2.0-7.1	210	Gallbladder / bile ducts	8	1.0	2.2	0.6-3.9	428
Liver	11	1.0	3.6	1.5-5.8	202	Skin (NMSC exc. SCC/BCC)	8	1.0	2.9	0.8-5.0	356
Thyroid gland	10	0.9	3.3	1.2-5.3	229	Stomach	7	0.8	2.0	0.5-3.6	497
						Myeloma	5	0.6	1.3	0.1-2.6	630
All cancers	1139	100.0	344.8	324-365	3	All cancers	827	100.0	265.6	247-284	4

Appendix 3D. Cancer incidence, Western Australia, 2006: Leading types by sex and geographic area

North Metro AHS

Males						Females					
	Cases	%	ASR	95%c.i.	Risk		Cases	%	ASR	95%c.i.	Risk
Prostate	726	32.3	120.3	111-129	7	Breast	519	29.7	85.0	77.4-92.5	11
Colorectal	239	10.6	39.2	34.1-44.3	21	Melanoma (skin)	198	11.3	31.5	26.9-36.2	30
Colon	149	6.6	24.6	20.5-28.6	32	Colorectal	197	11.3	25.9	21.9-29.9	35
Rectum	90	4.0	14.7	11.5-17.8	57	Colon	141	8.1	18.1	14.8-21.4	50
Melanoma (skin)	234	10.4	39.8	34.5-45.0	22	Rectum	55	3.1	7.6	5.5-9.8	115
Lung	208	9.2	31.8	27.3-36.3	26	Lung	136	7.8	17.6	14.4-20.8	50
Lymphoma	81	3.6	14.1	10.9-17.3	71	Lymphoma	72	4.1	11.3	8.5-14.1	84
Lymphoma NOS	3	0.1	0.4	0 - 0.8	6483	Lymphoma NOS	3	0.2	0.3	0 - 0.8	6404
Hodgkin lymphoma	7	0.3	1.4	0.3-2.5	990	Hodgkin lymphoma	9	0.5	2.4	0.8-3.9	674
NHL	71	3.2	12.3	9.3-15.3	77	NHL	60	3.4	8.6	6.3-10.9	97
Bladder & urinary tract	74	3.3	11.0	8.4-13.6	83	Unknown primary	64	3.7	7.8	5.7-10.0	119
Unknown primary	72	3.2	10.1	7.7-12.6	130	Uterus	61	3.5	9.0	6.6-11.4	96
Kidney	65	2.9	10.7	8.1-13.4	86	Pancreas	46	2.6	5.4	3.6-7.1	173
Stomach	52	2.3	8.3	6.0-10.6	102	Ovary	42	2.4	6.6	4.5-8.7	130
Leukaemia	51	2.3	8.8	6.3-11.4	101	Leukaemia	41	2.3	6.9	4.5-9.3	153
Leukaemia NOS	1	0.0	0.1	0 - 0.3	*	Leukaemia NOS	1	0.1	0.1	0 - 0.2	*
Lymphoid leukaemia	28	1.2	5.1	3.1-7.0	176	Lymphoid leukaemia	26	1.5	4.3	2.4-6.2	253
Myeloid leukaemia	22	1.0	3.7	2.1-5.3	236	Myeloid leukaemia	14	0.8	2.5	1.1-3.9	384
Leukaemia, other	0		0.0	0 - 0.0	-	Leukaemia, other	0		0.0	0 - 0.0	-
Lip, gum & mouth	38	1.7	6.5	4.4-8.6	130	Thyroid gland	35	2.0	6.4	4.2-8.7	167
Pancreas	37	1.6	5.8	3.9-7.8	162	Kidney	31	1.8	5.3	3.4-7.2	129
Liver	33	1.5	5.4	3.5-7.3	144	Brain	30	1.7	4.8	2.9-6.8	237
Testis	33	1.5	6.6	4.3-8.9	183	Stomach	27	1.5	3.6	2.1-5.0	207
Skin (NMSC exc. SCC/BCC)	29	1.3	4.2	2.6-5.8	297	Cervix	23	1.3	3.9	2.2-5.6	300
Mesothelioma	29	1.3	4.2	2.6-5.8	244	Bladder & urinary tract	21	1.2	2.2	1.1-3.2	516
Brain	29	1.3	5.0	3.1-6.9	220	Lip, gum & mouth	20	1.1	2.9	1.6-4.3	268
Oesophagus	26	1.2	4.3	2.6-6.1	172	Myelodysplastic diseases	18	1.0	2.0	1.0-3.0	508
Thyroid gland	22	1.0	4.0	2.3-5.7	256	Skin (NMSC exc. SCC/BCC)	17	1.0	2.3	1.1-3.5	410
Myeloma	21	0.9	3.3	1.8-4.7	321	Vulva	17	1.0	2.2	1.1-3.3	477
Pharynx	19	0.8	3.2	1.8-4.7	209	Myeloma	16	0.9	2.3	1.1-3.6	333
All cancers	2249	100.0	368.5	353-384	3	All cancers	1747	100.0	262.5	249-276	4

South Metro AHS

Males						Females					
	Cases	%	ASR	95%c.i.	Risk		Cases	%	ASR	95%c.i.	Risk
Prostate	592	28.7	102.6	94.0-111	8	Breast	470	28.4	86.6	78.5-94.8	11
Melanoma (skin)	228	11.0	42.5	36.8-48.2	21	Colorectal	195	11.8	29.0	24.5-33.4	29
Colorectal	225	10.9	39.2	33.9-44.5	22	Colon	146	8.8	21.0	17.3-24.8	41
Colon	144	7.0	24.8	20.6-29.0	37	Rectum	48	2.9	7.7	5.4-10.1	106
Rectum	81	3.9	14.4	11.2-17.6	51	Melanoma (skin)	153	9.2	29.2	24.3-34.0	32
Lung	207	10.0	35.4	30.4-40.5	22	Lung	124	7.5	19.4	15.7-23.0	40
Lymphoma	83	4.0	15.3	11.9-18.7	62	Lymphoma	69	4.2	11.8	8.7-14.8	94
Lymphoma NOS	2	0.1	0.4	0 - 0.9	2772	Lymphoma NOS	2	0.1	0.3	0 - 0.7	2830
Hodgkin lymphoma	4	0.2	1.1	0.0-2.3	1355	Hodgkin lymphoma	9	0.5	2.0	0.6-3.4	893
NHL	77	3.7	13.8	10.6-17.0	66	NHL	58	3.5	9.5	6.8-12.2	109
Unknown primary	69	3.3	11.7	8.8-14.6	83	Uterus	61	3.7	9.4	6.8-11.9	87
Bladder & urinary tract	65	3.1	10.1	7.5-12.7	85	Thyroid gland	57	3.4	12.2	8.9-15.5	83
Kidney	64	3.1	11.5	8.6-14.4	76	Ovary	54	3.3	9.6	6.9-12.4	92
Leukaemia	51	2.5	9.4	6.6-12.2	111	Unknown primary	51	3.1	6.4	4.4-8.5	193
Leukaemia NOS	2	0.1	0.2	0 - 0.6	*	Pancreas	43	2.6	6.0	4.0-8.0	142
Lymphoid leukaemia	33	1.6	5.8	3.7-8.0	167	Leukaemia	35	2.1	5.5	3.5-7.6	156
Myeloid leukaemia	16	0.8	3.4	1.6-5.2	330	Leukaemia NOS	1	0.1	0.1	0 - 0.2	*
Leukaemia, other	0		0.0	0 - 0.0	-	Lymphoid leukaemia	23	1.4	3.8	2.1-5.6	245
Lip, gum & mouth	46	2.2	9.4	6.6-12.2	110	Myeloid leukaemia	11	0.7	1.6	0.6-2.6	429
Pancreas	44	2.1	7.2	5.0-9.5	133	Leukaemia, other	0		0.0	0 - 0.0	-
Stomach	40	1.9	6.0	4.0-7.9	164	Cervix	31	1.9	5.8	3.6-8.0	201
Oesophagus	38	1.8	6.7	4.5-8.9	121	Kidney	30	1.8	5.2	3.1-7.3	174
Liver	30	1.5	5.0	3.1-6.8	169	Brain	27	1.6	5.8	3.5-8.1	143
Mesothelioma	27	1.3	4.5	2.8-6.3	206	Bladder & urinary tract	26	1.6	3.2	1.8-4.6	358
Brain	26	1.3	5.3	3.2-7.4	179	Lip, gum & mouth	22	1.3	3.9	2.2-5.6	247
Myeloma	26	1.3	4.2	2.5-5.9	207	Stomach	21	1.3	2.7	1.4-4.0	513
Larynx	22	1.1	3.6	2.0-5.2	275	Myeloma	20	1.2	2.9	1.5-4.3	275
Pharynx	20	1.0	3.8	2.1-5.5	199	Oesophagus	19	1.1	1.8	0.9-2.7	737
All cancers	2064	100.0	363.6	347-380	3	All cancers	1657	100.0	281.0	266-296	4

Appendix 3D. Cancer incidence, Western Australia, 2006: Leading types by sex and geographic area

WA Metro - all

	Males					Females					
	Cases	%	ASR	95%c.i.	Risk	Cases	%	ASR	95%c.i.	Risk	
Prostate	1318	30.6	111.9	106-118	8	Breast	989	29.1	85.9	80.3-91.4	11
Colorectal	464	10.8	39.2	35.5-42.9	21	Colorectal	392	11.5	27.4	24.4-30.3	32
Colon	293	6.8	24.7	21.7-27.6	34	Colon	287	8.4	19.5	17.0-22.0	45
Rectum	171	4.0	14.6	12.3-16.8	54	Rectum	103	3.0	7.7	6.1-9.3	111
Melanoma (skin)	462	10.7	41.0	37.1-44.8	22	Melanoma (skin)	351	10.3	30.4	27.1-33.8	31
Lung	415	9.6	33.6	30.2-36.9	24	Lung	260	7.6	18.4	16.0-20.8	44
Lymphoma	164	3.8	14.7	12.4-17.0	66	Lymphoma	141	4.1	11.5	9.4-13.6	88
Lymphoma NOS	5	0.1	0.4	0.0-0.7	3849	Lymphoma NOS	5	0.1	0.3	0.0-0.6	3906
Hodgkin lymphoma	11	0.3	1.3	0.5-2.1	1128	Hodgkin lymphoma	18	0.5	2.2	1.1-3.2	760
NHL	148	3.4	13.0	10.9-15.2	71	NHL	118	3.5	9.0	7.3-10.8	103
Unknown primary	141	3.3	10.9	9.0-12.8	102	Uterus	122	3.6	9.2	7.4-10.9	91
Bladder & urinary tract	139	3.2	10.6	8.7-12.4	84	Unknown primary	115	3.4	7.1	5.7-8.6	146
Kidney	129	3.0	11.1	9.1-13.1	81	Ovary	96	2.8	8.0	6.3-9.7	109
Leukaemia	102	2.4	9.1	7.2-11.0	105	Thyroid gland	92	2.7	9.1	7.2-11.1	113
Leukaemia NOS	3	0.1	0.2	0 - 0.3	*	Pancreas	89	2.6	5.7	4.4-7.0	156
Lymphoid leukaemia	61	1.4	5.5	4.0-6.9	170	Leukaemia	76	2.2	6.3	4.7-7.9	153
Myeloid leukaemia	38	0.9	3.5	2.3-4.7	275	Leukaemia NOS	2	0.1	0.1	0 - 0.1	*
Leukaemia, other	0		0.0	0 - 0.0	-	Lymphoid leukaemia	49	1.4	4.1	2.8-5.4	248
Stomach	92	2.1	7.2	5.6-8.7	125	Myeloid leukaemia	25	0.7	2.1	1.2-3.0	399
Lip, gum & mouth	84	1.9	7.8	6.1-9.5	121	Leukaemia, other	0		0.0	0 - 0.0	-
Pancreas	81	1.9	6.5	5.0-8.0	147	Kidney	61	1.8	5.2	3.8-6.6	148
Oesophagus	64	1.5	5.4	4.1-6.8	143	Brain	57	1.7	5.3	3.8-6.8	179
Liver	63	1.5	5.2	3.9-6.5	155	Cervix	54	1.6	4.8	3.4-6.1	245
Mesothelioma	56	1.3	4.3	3.2-5.5	224	Stomach	48	1.4	3.1	2.1-4.1	292
Brain	55	1.3	5.2	3.7-6.6	197	Bladder & urinary tract	47	1.4	2.6	1.8-3.5	428
Testis	50	1.2	5.4	3.9-6.9	228	Lip, gum & mouth	42	1.2	3.4	2.3-4.5	259
Myeloma	47	1.1	3.7	2.6-4.9	251	Myeloma	36	1.1	2.6	1.7-3.5	302
Skin (NMSC exc. SCC/BCC)	46	1.1	3.5	2.5-4.6	328	Myelodysplastic diseases	36	1.1	1.9	1.2-2.7	542
Pharynx	39	0.9	3.5	2.4-4.6	205	Skin (NMSC exc. SCC/BCC)	35	1.0	2.2	1.4-3.0	537
Larynx	37	0.9	3.1	2.0-4.1	296	Oesophagus	33	1.0	1.8	1.1-2.5	560
All cancers	4313	100.0	366.2	355-377	3	All cancers	3404	100.0	271.3	262-281	4

All Western Australia

	Males					Females					
	Cases	%	ASR	95%c.i.	Risk	Cases	%	ASR	95%c.i.	Risk	
Prostate	1635	30.0	107.7	102-113	8	Breast	1244	29.4	85.5	80.6-90.4	11
Melanoma (skin)	605	11.1	41.8	38.4-45.3	22	Colorectal	486	11.5	27.5	24.9-30.2	32
Colorectal	594	10.9	39.3	36.0-42.5	21	Colon	354	8.4	19.4	17.2-21.6	45
Colon	362	6.6	23.7	21.2-26.3	36	Rectum	130	3.1	7.9	6.5-9.4	112
Rectum	232	4.3	15.5	13.5-17.6	49	Melanoma (skin)	447	10.6	31.0	28.0-34.0	31
Lung	546	10.0	34.6	31.6-37.6	24	Lung	329	7.8	18.9	16.7-21.1	43
Lymphoma	207	3.8	14.4	12.4-16.4	65	Lymphoma	183	4.3	12.2	10.3-14.1	84
Lymphoma NOS	5	0.1	0.3	0.0-0.6	5047	Lymphoma NOS	5	0.1	0.3	0.0-0.5	4956
Hodgkin lymphoma	12	0.2	1.1	0.4-1.7	1228	Hodgkin lymphoma	28	0.7	2.8	1.7-3.9	575
NHL	190	3.5	13.0	11.1-15.0	69	NHL	150	3.5	9.1	7.6-10.7	100
Unknown primary	180	3.3	11.0	9.3-12.7	101	Uterus	160	3.8	9.7	8.1-11.2	87
Bladder & urinary tract	171	3.1	10.3	8.7-11.9	88	Unknown primary	142	3.4	7.0	5.7-8.3	157
Kidney	151	2.8	10.1	8.4-11.7	88	Ovary	117	2.8	7.8	6.3-9.3	107
Leukaemia	134	2.5	9.5	7.8-11.2	99	Thyroid gland	117	2.8	8.9	7.3-10.6	113
Leukaemia NOS	4	0.1	0.2	0 - 0.3	*	Pancreas	105	2.5	5.5	4.4-6.7	156
Lymphoid leukaemia	84	1.5	6.0	4.7-7.4	149	Leukaemia	91	2.1	6.0	4.7-7.4	161
Myeloid leukaemia	46	0.8	3.3	2.3-4.3	295	Leukaemia NOS	2	0.0	0.1	0 - 0.1	*
Leukaemia, other	0		0.0	0 - 0.0	-	Lymphoid leukaemia	60	1.4	4.1	2.9-5.2	245
Lip, gum & mouth	115	2.1	8.1	6.6-9.6	119	Myeloid leukaemia	29	0.7	1.9	1.2-2.7	471
Stomach	112	2.1	6.8	5.5-8.1	128	Leukaemia, other	0		0.0	0 - 0.0	-
Pancreas	105	1.9	6.8	5.4-8.1	131	Kidney	70	1.7	4.8	3.6-5.9	163
Oesophagus	91	1.7	6.0	4.7-7.3	134	Cervix	67	1.6	4.8	3.6-6.1	238
Liver	74	1.4	4.9	3.7-6.0	164	Brain	66	1.6	4.8	3.5-6.0	202
Brain	68	1.2	5.0	3.7-6.2	201	Bladder & urinary tract	59	1.4	2.7	2.0-3.5	394
Mesothelioma	65	1.2	3.9	2.9-4.9	251	Lip, gum & mouth	55	1.3	3.6	2.6-4.6	230
Skin (NMSC exc. SCC/BCC)	60	1.1	3.7	2.7-4.7	286	Stomach	55	1.3	2.9	2.1-3.7	319
Testis	58	1.1	5.1	3.7-6.5	254	Skin (NMSC exc. SCC/BCC)	43	1.0	2.3	1.6-3.1	488
Myeloma	56	1.0	3.5	2.6-4.5	261	Myeloma	41	1.0	2.4	1.6-3.1	339
Pharynx	55	1.0	3.8	2.8-4.8	196	Myelodysplastic diseases	39	0.9	1.8	1.2-2.4	575
Larynx	51	0.9	3.3	2.4-4.2	265	Oesophagus	36	0.9	1.6	1.0-2.2	652
All cancers	5457	100.0	362.0	352-372	3	All cancers	4235	100.0	270.3	262-279	4

Appendix 3E. Cancer mortality, Western Australia, 2006: Leading types by sex and geographic area

CHS Kimberley Region

Males						Females					
	Cases	%	ASR	95%c.i.	Risk		Cases	%	ASR	95%c.i.	Risk
Colorectal	3	17.6	22.2	0 - 47.9	21	Breast	3	27.3	17.9	0 - 39.0	127
Colon	0		0.0	0 - 0.0	-	Lung	2	18.2	16.3	0 - 38.9	*
Rectum	3	17.6	22.2	0 - 47.9	21	Colorectal	1	9.1	8.4	0 - 24.8	*
Tongue	2	11.8	9.6	0 - 22.9	93	Colon	1	9.1	8.4	0 - 24.8	*
Lung	2	11.8	13.5	0 - 32.8	40	Rectum	0		0.0	0 - 0.0	-
Melanoma (skin)	2	11.8	13.1	0 - 32.2	39	Stomach	1	9.1	8.4	0 - 24.8	*
Myeloprolif. d/o (chronic)	2	11.8	14.0	0 - 33.4	112	Gallbladder / bile ducts	1	9.1	8.6	0 - 25.4	*
Pharynx	1	5.9	5.0	0 - 14.9	159	Pancreas	1	9.1	5.2	0 - 15.3	233
Gallbladder / bile ducts	1	5.9	6.8	0 - 20.2	*	Cervix	1	9.1	5.2	0 - 15.3	233
Pancreas	1	5.9	4.7	0 - 13.8	257	Unknown primary	1	9.1	8.4	0 - 24.8	*
Prostate	1	5.9	7.9	0 - 23.4	*						
Brain	1	5.9	4.6	0 - 13.5	220						
Lymphoma	1	5.9	7.7	0 - 22.8	78						
Lymphoma NOS	0		0.0	0 - 0.0	-						
Hodgkin lymphoma	0		0.0	0 - 0.0	-						
NHL	1	5.9	7.7	0 - 22.8	78						
All cancers	17	100.0	109.2	56.0-162	7	All cancers	11	100.0	78.4	31.5-125	61

CHS Pilbara Region

Males						Females					
	Cases	%	ASR	95%c.i.	Risk		Cases	%	ASR	95%c.i.	Risk
Prostate	3	23.1	33.1	0 - 75.9	251	Lung	3	23.1	38.9	0 - 88.0	20
Colorectal	2	15.4	12.9	0 - 30.7	63	Breast	3	23.1	30.0	0 - 66.9	35
Colon	1	7.7	6.4	0 - 19.0	125	Cervix	2	15.4	9.2	0 - 22.1	101
Rectum	1	7.7	6.4	0 - 19.0	125	Major salivary glands	1	7.7	4.3	0 - 12.6	281
Unknown primary	2	15.4	22.8	0 - 54.3	*	Pharynx	1	7.7	5.5	0 - 16.2	147
Oesophagus	1	7.7	6.4	0 - 19.0	125	Oesophagus	1	7.7	19.0	0 - 56.2	22
Liver	1	7.7	10.0	0 - 29.7	60	Stomach	1	7.7	4.3	0 - 12.6	281
Mesothelioma	1	7.7	6.4	0 - 19.0	125	Mesothelioma	1	7.7	19.0	0 - 56.2	22
Thyroid gland	1	7.7	10.6	0 - 31.4	*						
Lymphoma	1	7.7	10.6	0 - 31.4	*						
Lymphoma NOS	0		0.0	0 - 0.0	-						
Hodgkin lymphoma	1	7.7	10.6	0 - 31.4	*						
NHL	0		0.0	0 - 0.0	-						
Leukaemia	1	7.7	10.0	0 - 29.7	60						
Leukaemia NOS	0		0.0	0 - 0.0	-						
Lymphoid leukaemia	0		0.0	0 - 0.0	-						
Myeloid leukaemia	1	7.7	10.0	0 - 29.7	60						
All cancers	13	100.0	123.0	52.1-194	15	All cancers	13	100.0	130.2	47.2-213	6

CHS Midwest Region

Males						Females					
	Cases	%	ASR	95%c.i.	Risk		Cases	%	ASR	95%c.i.	Risk
Lung	22	28.9	46.0	26.4-65.6	18	Lung	15	26.3	31.3	14.9-47.6	30
Prostate	11	14.5	19.7	7.6-31.9	57	Breast	13	22.8	33.0	14.9-51.1	21
Colorectal	6	7.9	9.1	1.6-16.5	260	Colorectal	5	8.8	9.0	0.7-17.2	273
Colon	3	3.9	5.0	0 - 10.8	260	Colon	3	5.3	4.5	0 - 9.6	*
Rectum	3	3.9	4.1	0 - 8.6	*	Rectum	2	3.5	4.5	0 - 11.0	273
Pancreas	6	7.9	13.9	2.8-25.1	41	Pancreas	3	5.3	8.1	0 - 17.3	71
Mesothelioma	5	6.6	11.5	1.2-21.8	121	Lymphoma	3	5.3	6.1	0 - 13.1	114
Melanoma (skin)	3	3.9	6.6	0 - 14.3	317	Lymphoma NOS	0		0.0	0 - 0.0	-
Kidney	3	3.9	4.7	0 - 10.2	189	Hodgkin lymphoma	0		0.0	0 - 0.0	-
Brain	3	3.9	9.2	0 - 20.1	103	NHL	3	5.3	6.1	0 - 13.1	114
Oesophagus	2	2.6	3.8	0 - 9.2	489	Cervix	2	3.5	5.1	0 - 12.1	194
Stomach	2	2.6	3.8	0 - 9.2	486	Bladder & urinary tract	2	3.5	3.9	0 - 9.5	168
Gallbladder / bile ducts	2	2.6	3.8	0 - 9.4	317	Brain	2	3.5	5.0	0 - 11.9	124
Myeloma	2	2.6	4.4	0 - 10.6	110	Unknown primary	2	3.5	2.9	0 - 7.0	*
						Leukaemia	2	3.5	2.7	0 - 6.3	*
All cancers	76	100.0	153.9	118-190	7	All cancers	57	100.0	122.9	90.0-156	8

Appendix 3E. Cancer mortality, Western Australia, 2006: Leading types by sex and geographic area

CHS Wheatbelt Region

Males						Females					
	Cases	%	ASR	95%c.i.	Risk		Cases	%	ASR	95%c.i.	Risk
Lung	20	23.5	26.6	14.7-38.4	33	Colorectal	9	17.6	11.5	3.3-19.6	72
Prostate	16	18.8	21.7	10.9-32.6	37	Colon	7	13.7	8.8	1.7-15.8	93
Colorectal	11	12.9	13.3	5.3-21.4	168	Rectum	2	3.9	2.7	0 - 6.8	315
Colon	7	8.2	8.3	2.0-14.7	464	Lung	7	13.7	11.9	2.9-21.0	63
Rectum	4	4.7	5.0	0.0-10.0	264	Breast	6	11.8	9.2	1.4-17.0	175
Oesophagus	4	4.7	6.2	0.1-12.2	72	Unknown primary	5	9.8	7.2	0.5-13.9	93
Leukaemia	4	4.7	5.1	0 - 10.3	155	Ovary	4	7.8	5.4	0 - 10.9	261
Leukaemia NOS	0		0.0	0 - 0.0	-	Uterus	3	5.9	4.8	0 - 10.6	198
Lymphoid leukaemia	2	2.4	2.6	0 - 6.2	264	Stomach	2	3.9	2.7	0 - 6.8	315
Myeloid leukaemia	2	2.4	2.6	0 - 6.2	372	Pancreas	2	3.9	3.6	0 - 8.6	224
Leukaemia, other	0		0.0	0 - 0.0	-	Melanoma (skin)	2	3.9	3.0	0 - 7.8	529
Pancreas	3	3.5	4.7	0 - 10.1	110	Kidney	2	3.9	3.0	0 - 7.4	315
Bladder & urinary tract	3	3.5	4.5	0 - 9.5	264	Bladder & urinary tract	2	3.9	1.6	0 - 3.7	*
Lymphoma	3	3.5	4.3	0 - 9.3	165						
Lymphoma NOS	0		0.0	0 - 0.0	-						
Hodgkin lymphoma	0		0.0	0 - 0.0	-						
NHL	3	3.5	4.3	0 - 9.3	165						
All cancers	85	100.0	116.8	91.6-142	8	All cancers	51	100.0	73.1	51.6-94.6	13

CHS Goldfields Region

Males						Females					
	Cases	%	ASR	95%c.i.	Risk		Cases	%	ASR	95%c.i.	Risk
Lung	7	17.5	23.6	5.9-41.2	33	Gallbladder / bile ducts	3	13.6	9.0	0 - 19.7	90
Colorectal	5	12.5	19.1	2.1-36.0	60	Lung	3	13.6	7.9	0 - 17.0	354
Colon	3	7.5	10.4	0 - 22.6	155	Colorectal	2	9.1	7.9	0 - 18.8	72
Rectum	2	5.0	8.6	0 - 20.5	97	Colon	1	4.5	3.4	0 - 10.1	354
Unknown primary	5	12.5	15.8	1.9-29.7	134	Rectum	1	4.5	4.5	0 - 13.2	90
Prostate	4	10.0	16.4	0.4-32.4	27	Breast	2	9.1	6.8	0 - 17.0	168
Pharynx	2	5.0	6.0	0 - 14.5	134	Ovary	2	9.1	7.9	0 - 19.1	122
Stomach	2	5.0	6.9	0 - 16.5	155	Myeloma	2	9.1	6.6	0 - 15.8	121
Kidney	2	5.0	4.9	0 - 11.7	196	Tongue	1	4.5	2.9	0 - 8.7	*
Bladder & urinary tract	2	5.0	7.4	0 - 17.8	92	Pharynx	1	4.5	4.5	0 - 13.2	90
Lip, gum & mouth	1	2.5	3.9	0 - 11.5	155	Melanoma (skin)	1	4.5	3.4	0 - 10.1	354
Oesophagus	1	2.5	2.5	0 - 7.3	325	Peritoneum/retro-p.	1	4.5	4.9	0 - 14.6	122
Small intestine	1	2.5	3.9	0 - 11.5	155	Kidney	1	4.5	2.9	0 - 8.7	*
Liver	1	2.5	2.4	0 - 7.2	494	Brain	1	4.5	4.5	0 - 13.2	90
Gallbladder / bile ducts	1	2.5	4.2	0 - 12.3	97	Unknown primary	1	4.5	4.9	0 - 14.6	122
Pancreas	1	2.5	3.5	0 - 10.5	226	Leukaemia	1	4.5	2.3	0 - 6.7	*
Melanoma (skin)	1	2.5	4.5	0 - 13.2	*						
All cancers	40	100.0	137.7	94.5-181	6	All cancers	22	100.0	76.5	43.3-110	11

CHS Great Southern Region

Males						Females					
	Cases	%	ASR	95%c.i.	Risk		Cases	%	ASR	95%c.i.	Risk
Prostate	11	19.6	16.6	6.5-26.8	68	Colorectal	11	20.8	20.4	7.3-33.5	47
Lung	9	16.1	17.1	5.3-29.0	53	Colon	7	13.2	11.6	2.2-21.0	80
Colorectal	6	10.7	10.9	1.9-20.0	92	Rectum	4	7.5	8.8	0 - 17.9	110
Colon	2	3.6	3.0	0 - 7.1	*	Lung	11	20.8	17.3	6.3-28.3	50
Rectum	4	7.1	8.0	0 - 16.0	92	Breast	9	17.0	21.0	6.8-35.1	36
Melanoma (skin)	5	8.9	10.3	1.0-19.6	68	Brain	3	5.7	5.4	0 - 12.0	107
Stomach	3	5.4	4.5	0 - 9.7	202	Liver	2	3.8	4.6	0 - 11.0	107
Gallbladder / bile ducts	3	5.4	5.4	0 - 11.8	155	Cervix	2	3.8	2.1	0 - 5.0	*
Pancreas	3	5.4	4.3	0 - 9.4	393	Ovary	2	3.8	3.1	0 - 7.7	357
Leukaemia	3	5.4	4.0	0 - 8.6	*	Lymphoma	2	3.8	1.8	0 - 4.2	*
Leukaemia NOS	0		0.0	0 - 0.0	-	Lymphoma NOS	0		0.0	0 - 0.0	-
Lymphoid leukaemia	0		0.0	0 - 0.0	-	Hodgkin lymphoma	0		0.0	0 - 0.0	-
Myeloid leukaemia	3	5.4	4.0	0 - 8.6	*	NHL	2	3.8	1.8	0 - 4.2	*
Leukaemia, other	0		0.0	0 - 0.0	-						
All cancers	56	100.0	99.4	72.2-127	10	All cancers	53	100.0	88.3	62.3-114	10

Appendix 3E. Cancer mortality, Western Australia, 2006: Leading types by sex and geographic area

CHS South West Region

Males						Females					
	Cases	%	ASR	95%c.i.	Risk		Cases	%	ASR	95%c.i.	Risk
Lung	27	20.5	21.2	12.9-29.4	40	Breast	19	17.6	13.9	6.6-21.3	122
Colorectal	17	12.9	15.9	8.2-23.7	52	Lung	17	15.7	12.7	6.1-19.2	81
Colon	12	9.1	10.4	4.4-16.5	86	Colorectal	14	13.0	9.4	4.0-14.7	160
Rectum	5	3.8	5.5	0.7-10.3	130	Colon	8	7.4	4.7	1.2-8.2	673
Prostate	15	11.4	10.8	5.2-16.4	107	Rectum	6	5.6	4.7	0.6-8.7	210
Pancreas	11	8.3	9.3	3.7-15.0	88	Unknown primary	7	6.5	3.7	0.8-6.6	871
Oesophagus	8	6.1	7.2	2.1-12.3	97	Lymphoma	7	6.5	5.4	1.1-9.8	171
Mesothelioma	6	4.5	4.7	0.8-8.5	263	Lymphoma NOS	0		0.0	0 - 0.0	-
Melanoma (skin)	5	3.8	4.0	0.3-7.7	165	Hodgkin lymphoma	0		0.0	0 - 0.0	-
Brain	5	3.8	4.6	0.4-8.8	130	NHL	7	6.5	5.4	1.1-9.8	171
Leukaemia	5	3.8	4.7	0.5-9.0	160	Pancreas	6	5.6	4.4	0.6-8.2	257
Leukaemia NOS	0		0.0	0 - 0.0	-	Stomach	5	4.6	3.7	0.3-7.2	214
Lymphoid leukaemia	4	3.0	3.5	0.0-6.9	193	Ovary	5	4.6	4.7	0.5-8.9	170
Myeloid leukaemia	1	0.8	1.3	0 - 3.8	927	Melanoma (skin)	4	3.7	3.0	0 - 6.1	237
Leukaemia, other	0		0.0	0 - 0.0	-	Bladder & urinary tract	3	2.8	1.4	0 - 2.9	*
Unknown primary	4	3.0	3.1	0 - 6.3	268	Small intestine	2	1.9	2.2	0 - 5.3	272
Lymphoma	4	3.0	3.0	0 - 6.0	293	Skin (non-melanoma; includes:	2	1.9	0.8	0 - 1.9	*
Lymphoma NOS	0		0.0	0 - 0.0	-	Mesothelioma	2	1.9	1.6	0 - 4.1	673
Hodgkin lymphoma	0		0.0	0 - 0.0	-	Brain	2	1.9	3.1	0 - 7.7	519
NHL	4	3.0	3.0	0 - 6.0	293	Leukaemia	2	1.9	2.3	0 - 5.5	301
Myelodysplastic diseases	4	3.0	3.5	0.0-7.0	243	Leukaemia NOS	0		0.0	0 - 0.0	-
Stomach	3	2.3	3.0	0 - 6.3	437	Lymphoid leukaemia	2	1.9	2.3	0 - 5.5	301
Larynx	3	2.3	2.1	0 - 4.8	721	Myeloid leukaemia	0		0.0	0 - 0.0	-
Skin (non-melanoma; includes:	3	2.3	2.1	0 - 4.7	427	Leukaemia, other	0		0.0	0 - 0.0	-
Bladder & urinary tract	2	1.5	1.2	0 - 2.9	*	Myeloma	2	1.9	1.3	0 - 3.3	421
Myeloma	2	1.5	1.3	0 - 3.2	*	Myelodysplastic diseases	2	1.9	0.8	0 - 2.0	*
All cancers	132	100.0	109.3	90.1-129	9	All cancers	108	100.0	80.2	63.5-97.0	14

WA Country - all

Males						Females					
	Cases	%	ASR	95%c.i.	Risk		Cases	%	ASR	95%c.i.	Risk
Lung	87	20.8	24.8	19.4-30.1	34	Lung	58	18.4	15.9	11.6-20.3	60
Prostate	61	14.6	16.4	12.2-20.6	58	Breast	55	17.5	16.3	11.8-20.9	61
Colorectal	50	11.9	14.1	10.1-18.1	72	Colorectal	42	13.3	11.1	7.5-14.6	101
Colon	28	6.7	7.7	4.8-10.7	169	Colon	27	8.6	6.6	3.9-9.3	202
Rectum	22	5.3	6.4	3.6-9.1	125	Rectum	15	4.8	4.5	2.1-6.8	200
Pancreas	25	6.0	7.4	4.5-10.4	98	Unknown primary	17	5.4	4.0	1.9-6.0	311
Melanoma (skin)	18	4.3	5.1	2.7-7.5	168	Ovary	14	4.4	3.9	1.7-6.0	262
Oesophagus	16	3.8	4.8	2.4-7.2	136	Pancreas	12	3.8	3.7	1.5-6.0	220
Unknown primary	16	3.8	4.1	2.0-6.1	315	Lymphoma	12	3.8	3.1	1.2-4.9	305
Mesothelioma	15	3.6	4.4	2.1-6.6	241	Lymphoma NOS	0		0.0	0 - 0.0	-
Leukaemia	14	3.3	3.8	1.7-5.8	254	Hodgkin lymphoma	0		0.0	0 - 0.0	-
Leukaemia NOS	1	0.2	0.2	0 - 0.5	*	NHL	12	3.8	3.1	1.2-4.9	305
Lymphoid leukaemia	6	1.4	1.7	0.3-3.0	400	Stomach	10	3.2	2.6	0.9-4.3	386
Myeloid leukaemia	7	1.7	1.9	0.4-3.4	694	Melanoma (skin)	8	2.5	2.2	0.6-3.7	474
Leukaemia, other	0		0.0	0 - 0.0	-	Cervix	8	2.5	2.4	0.7-4.1	399
Stomach	12	2.9	3.4	1.4-5.4	318	Bladder & urinary tract	8	2.5	1.6	0.4-2.8	1148
Bladder & urinary tract	10	2.4	3.0	1.1-4.9	313	Brain	8	2.5	2.9	0.8-4.9	242
Brain	10	2.4	3.4	1.2-5.6	218	Gallbladder / bile ducts	6	1.9	1.3	0.2-2.5	574
Kidney	9	2.1	2.5	0.8-4.1	343	Leukaemia	6	1.9	1.4	0.2-2.7	856
Lymphoma	9	2.1	2.4	0.8-4.0	342	Leukaemia NOS	0		0.0	0 - 0.0	-
Lymphoma NOS	0		0.0	0 - 0.0	-	Lymphoid leukaemia	2	0.6	0.8	0 - 1.9	856
Hodgkin lymphoma	1	0.2	0.2	0 - 0.6	*	Myeloid leukaemia	4	1.3	0.6	0.0-1.2	*
NHL	8	1.9	2.2	0.7-3.8	342	Leukaemia, other	0		0.0	0 - 0.0	-
Gallbladder / bile ducts	8	1.9	2.2	0.6-3.7	467	Myeloma	6	1.9	1.5	0.2-2.7	610
Skin (non-melanoma; includes:	8	1.9	2.1	0.6-3.6	625	Uterus	5	1.6	1.6	0.1-3.1	439
Myeloma	7	1.7	2.0	0.5-3.6	336	Skin (non-melanoma; includes:	4	1.3	0.6	0.0-1.3	*
Tongue	6	1.4	1.8	0.3-3.3	444	Kidney	4	1.3	1.2	0 - 2.3	655
Lip, gum & mouth	5	1.2	1.4	0.1-2.7	856						
Myelodysplastic diseases	5	1.2	1.5	0.2-2.8	727						
All cancers	419	100.0	118.3	107-130	8	All cancers	315	100.0	86.6	76.4-96.7	12

Appendix 3E. Cancer mortality, Western Australia, 2006: Leading types by sex and geographic area

North Metro AHS

Males

	Cases	%	ASR	95%c.i.	Risk
Lung	184	22.6	27.4	23.3-31.5	34
Prostate	92	11.3	11.7	9.2-14.2	132
Colorectal	80	9.8	12.3	9.5-15.0	74
Colon	51	6.3	7.6	5.4-9.7	135
Rectum	29	3.6	4.7	2.9-6.5	163
Pancreas	41	5.0	6.1	4.2-8.1	144
Bladder & urinary tract	39	4.8	5.2	3.5-7.0	264
Stomach	36	4.4	5.6	3.7-7.4	168
Unknown primary	33	4.1	4.4	2.8-6.0	408
Melanoma (skin)	32	3.9	5.0	3.2-6.8	223
Mesothelioma	29	3.6	4.4	2.7-6.1	190
Brain	29	3.6	4.7	2.9-6.5	209
Lymphoma	29	3.6	4.4	2.7-6.1	236
Lymphoma NOS	3	0.4	0.3	0 - 0.6	*
Hodgkin lymphoma	1	0.1	0.1	0 - 0.4	*
NHL	25	3.1	4.0	2.4-5.6	236
Leukaemia	28	3.4	4.2	2.6-5.8	251
Leukaemia NOS	1	0.1	0.1	0 - 0.3	*
Lymphoid leukaemia	9	1.1	1.4	0.5-2.4	782
Myeloid leukaemia	18	2.2	2.7	1.4-4.0	369
Leukaemia, other	0	0.0	0.0	0 - 0.0	-
Oesophagus	22	2.7	3.8	2.2-5.5	214
Liver	22	2.7	3.5	2.0-5.0	223
Kidney	20	2.5	3.0	1.6-4.3	446
Myelodysplastic diseases	15	1.8	2.2	1.1-3.4	419
Skin (non-melanoma; includes	14	1.7	2.1	0.9-3.2	599
Myeloma	13	1.6	1.7	0.7-2.7	1149
Gallbladder / bile ducts	9	1.1	1.3	0.4-2.2	760
Pharynx	7	0.9	1.2	0.3-2.1	490
All cancers	814	100.0	120.7	112-129	9

Females

	Cases	%	ASR	95%c.i.	Risk
Lung	106	17.3	13.3	10.5-16.1	70
Breast	92	15.1	14.0	11.0-17.0	62
Colorectal	74	12.1	9.2	6.9-11.6	98
Colon	52	8.5	6.7	4.7-8.7	134
Rectum	22	3.6	2.6	1.4-3.8	361
Pancreas	43	7.0	4.7	3.1-6.3	231
Unknown primary	35	5.7	3.9	2.5-5.4	271
Ovary	33	5.4	5.2	3.3-7.0	131
Lymphoma	21	3.4	2.6	1.3-3.9	708
Lymphoma NOS	0	0.0	0.0	0 - 0.0	-
Hodgkin lymphoma	0	0.0	0.0	0 - 0.0	-
NHL	21	3.4	2.6	1.3-3.9	708
Melanoma (skin)	20	3.3	3.0	1.6-4.4	255
Oesophagus	16	2.6	1.7	0.8-2.7	625
Myelodysplastic diseases	16	2.6	1.5	0.7-2.4	671
Stomach	14	2.3	1.7	0.7-2.6	589
Uterus	14	2.3	2.2	1.0-3.4	434
Brain	14	2.3	2.0	0.7-3.4	638
Bladder & urinary tract	13	2.1	0.9	0.4-1.4	*
Leukaemia	13	2.1	1.8	0.7-2.8	661
Leukaemia NOS	0	0.0	0.0	0 - 0.0	-
Lymphoid leukaemia	6	1.0	0.7	0.1-1.3	2044
Myeloid leukaemia	7	1.1	1.1	0.2-1.9	976
Leukaemia, other	0	0.0	0.0	0 - 0.0	-
Liver	11	1.8	1.3	0.5-2.2	838
Kidney	11	1.8	1.5	0.6-2.4	488
Gallbladder / bile ducts	10	1.6	1.1	0.3-1.9	1429
Cervix	7	1.1	0.9	0.2-1.6	1427
Myeloma	7	1.1	0.8	0.2-1.5	1821
All cancers	611	100.0	78.2	71.3-85.0	13

South Metro AHS

Males

	Cases	%	ASR	95%c.i.	Risk
Lung	187	23.0	30.1	25.6-34.6	29
Prostate	99	12.2	12.8	10.2-15.5	149
Colorectal	74	9.1	12.0	9.2-14.9	81
Colon	46	5.7	7.4	5.2-9.7	140
Rectum	28	3.4	4.6	2.8-6.4	193
Pancreas	47	5.8	7.5	5.2-9.7	127
Oesophagus	35	4.3	6.0	4.0-8.1	135
Stomach	35	4.3	5.0	3.3-6.8	241
Leukaemia	35	4.3	6.0	3.9-8.0	162
Leukaemia NOS	3	0.4	0.4	0 - 1.0	4962
Lymphoid leukaemia	11	1.4	1.7	0.6-2.7	635
Myeloid leukaemia	21	2.6	3.9	2.1-5.6	226
Leukaemia, other	0	0.0	0.0	0 - 0.0	-
Melanoma (skin)	33	4.1	5.4	3.5-7.4	190
Unknown primary	31	3.8	4.8	3.0-6.6	244
Bladder & urinary tract	27	3.3	4.0	2.4-5.5	336
Lymphoma	25	3.1	4.4	2.6-6.2	196
Lymphoma NOS	1	0.1	0.1	0 - 0.4	*
Hodgkin lymphoma	1	0.1	0.1	0 - 0.3	*
NHL	23	2.8	4.1	2.4-5.9	196
Liver	24	2.9	3.8	2.2-5.5	256
Myelodysplastic diseases	23	2.8	3.2	1.9-4.6	467
Brain	21	2.6	4.5	2.5-6.5	164
Myeloma	19	2.3	3.0	1.6-4.5	302
Skin (non-melanoma; includes	16	2.0	2.5	1.2-3.8	413
Mesothelioma	14	1.7	2.2	1.0-3.4	426
Kidney	12	1.5	1.6	0.7-2.5	878
Gallbladder / bile ducts	10	1.2	1.3	0.4-2.1	1170
All cancers	814	100.0	128.6	119-138	8

Females

	Cases	%	ASR	95%c.i.	Risk
Lung	98	16.4	14.2	11.2-17.3	56
Breast	82	13.7	13.8	10.6-17.0	65
Colorectal	80	13.4	10.3	7.8-12.8	85
Colon	51	8.5	6.1	4.2-8.0	166
Rectum	29	4.9	4.3	2.6-5.9	173
Pancreas	47	7.9	6.0	4.1-8.0	156
Unknown primary	40	6.7	4.5	2.9-6.0	250
Ovary	24	4.0	3.7	2.1-5.3	194
Lymphoma	24	4.0	2.8	1.5-4.1	418
Lymphoma NOS	1	0.2	0.1	0 - 0.2	*
Hodgkin lymphoma	0	0.0	0.0	0 - 0.0	-
NHL	23	3.9	2.7	1.5-4.0	418
Leukaemia	22	3.7	3.6	1.9-5.3	292
Leukaemia NOS	1	0.2	0.1	0 - 0.2	*
Lymphoid leukaemia	10	1.7	1.6	0.4-2.7	950
Myeloid leukaemia	11	1.8	2.0	0.7-3.2	422
Leukaemia, other	0	0.0	0.0	0 - 0.0	-
Stomach	19	3.2	2.6	1.3-3.9	392
Melanoma (skin)	17	2.8	2.5	1.2-3.9	341
Brain	16	2.7	3.3	1.6-4.9	245
Oesophagus	13	2.2	1.5	0.6-2.4	753
Cervix	12	2.0	1.8	0.7-3.0	505
Uterus	12	2.0	1.8	0.6-2.9	420
Myelodysplastic diseases	12	2.0	2.1	0.6-3.6	464
Bladder & urinary tract	10	1.7	0.9	0.3-1.5	4596
Myeloma	10	1.7	1.1	0.3-1.8	1379
Liver	8	1.3	1.0	0.2-1.8	936
All cancers	597	100.0	85.6	77.9-93.3	11

Appendix 3E. Cancer mortality, Western Australia, 2006: Leading types by sex and geographic area

WA Metro - all

Males						Females					
	Cases	%	ASR	95%c.i.	Risk		Cases	%	ASR	95%c.i.	Risk
Lung	371	22.8	28.7	25.7-31.8	32	Lung	204	16.9	13.7	11.7-15.8	63
Prostate	191	11.7	12.2	10.4-14.1	140	Breast	174	14.4	13.9	11.7-16.1	63
Colorectal	154	9.5	12.1	10.1-14.1	78	Colorectal	154	12.7	9.8	8.1-11.5	91
Colon	97	6.0	7.5	5.9-9.1	138	Colon	103	8.5	6.4	5.0-7.8	147
Rectum	57	3.5	4.7	3.4-5.9	176	Rectum	51	4.2	3.4	2.4-4.4	237
Pancreas	88	5.4	6.8	5.3-8.3	135	Pancreas	90	7.5	5.4	4.1-6.6	187
Stomach	71	4.4	5.3	4.0-6.6	197	Unknown primary	75	6.2	4.2	3.1-5.3	260
Bladder & urinary tract	66	4.1	4.6	3.5-5.8	294	Ovary	57	4.7	4.5	3.2-5.7	156
Melanoma (skin)	65	4.0	5.2	3.9-6.5	206	Lymphoma	45	3.7	2.7	1.8-3.6	527
Unknown primary	64	3.9	4.6	3.4-5.8	307	Lymphoma NOS	1	0.1	0.0	0 - 0.1	*
Leukaemia	63	3.9	5.1	3.8-6.4	198	Hodgkin lymphoma	0		0.0	0 - 0.0	-
Leukaemia NOS	4	0.2	0.2	0 - 0.5	*	NHL	44	3.6	2.7	1.7-3.6	527
Lymphoid leukaemia	20	1.2	1.6	0.8-2.3	698	Melanoma (skin)	37	3.1	2.8	1.8-3.7	290
Myeloid leukaemia	39	2.4	3.2	2.2-4.3	282	Leukaemia	35	2.9	2.6	1.7-3.6	412
Leukaemia, other	0		0.0	0 - 0.0	-	Leukaemia NOS	1	0.1	0.0	0 - 0.1	*
Oesophagus	57	3.5	4.9	3.6-6.2	166	Lymphoid leukaemia	16	1.3	1.1	0.5-1.7	1328
Lymphoma	54	3.3	4.4	3.2-5.6	214	Myeloid leukaemia	18	1.5	1.5	0.8-2.3	597
Lymphoma NOS	4	0.2	0.2	0 - 0.4	*	Leukaemia, other	0		0.0	0 - 0.0	-
Hodgkin lymphoma	2	0.1	0.1	0 - 0.3	*	Stomach	33	2.7	2.1	1.3-2.9	475
NHL	48	2.9	4.1	2.9-5.2	214	Brain	30	2.5	2.6	1.6-3.7	361
Brain	50	3.1	4.6	3.3-5.9	183	Oesophagus	29	2.4	1.6	0.9-2.2	682
Liver	46	2.8	3.7	2.6-4.8	239	Myelodysplastic diseases	28	2.3	1.8	1.0-2.6	556
Mesothelioma	43	2.6	3.3	2.3-4.3	260	Uterus	26	2.2	2.0	1.2-2.8	422
Myelodysplastic diseases	38	2.3	2.7	1.8-3.6	443	Bladder & urinary tract	23	1.9	0.9	0.5-1.3	9885
Kidney	32	2.0	2.3	1.5-3.2	578	Liver	19	1.6	1.2	0.6-1.8	874
Myeloma	32	2.0	2.4	1.5-3.2	482	Cervix	19	1.6	1.3	0.7-2.0	758
Skin (non-melanoma; includes)	30	1.8	2.3	1.4-3.1	490	Myeloma	17	1.4	0.9	0.4-1.4	1577
Gallbladder / bile ducts	19	1.2	1.3	0.7-1.9	915	Kidney	15	1.2	1.1	0.5-1.7	723
Pharynx	14	0.9	1.1	0.5-1.7	709	Gallbladder / bile ducts	13	1.1	0.7	0.3-1.2	1975
Lip, gum & mouth	13	0.8	1.2	0.5-1.8	671	Mesothelioma	11	0.9	0.9	0.3-1.5	882
All cancers	1628	100.0	124.6	118-131	9	All cancers	1208	100.0	81.7	76.5-86.8	12

All Western Australia

Males						Females					
	Cases	%	ASR	95%c.i.	Risk		Cases	%	ASR	95%c.i.	Risk
Lung	458	22.4	27.9	25.2-30.5	32	Lung	262	17.2	14.2	12.3-16.0	62
Prostate	252	12.3	13.2	11.5-14.8	107	Breast	229	15.0	14.3	12.4-16.3	63
Colorectal	204	10.0	12.5	10.7-14.3	76	Colorectal	196	12.9	10.0	8.5-11.5	93
Colon	125	6.1	7.5	6.2-8.9	144	Colon	130	8.5	6.4	5.2-7.6	156
Rectum	79	3.9	5.0	3.9-6.1	162	Rectum	66	4.3	3.6	2.7-4.5	227
Pancreas	113	5.5	7.0	5.6-8.3	124	Pancreas	102	6.7	5.1	4.0-6.2	192
Stomach	83	4.1	4.9	3.8-6.0	216	Unknown primary	92	6.0	4.1	3.2-5.1	269
Melanoma (skin)	83	4.1	5.1	4.0-6.3	196	Ovary	71	4.7	4.3	3.3-5.4	169
Unknown primary	80	3.9	4.5	3.5-5.5	309	Lymphoma	57	3.7	2.8	1.9-3.6	460
Leukaemia	77	3.8	4.8	3.7-5.9	208	Lymphoma NOS	1	0.1	0.0	0 - 0.1	*
Leukaemia NOS	5	0.2	0.2	0.0-0.4	*	Hodgkin lymphoma	0		0.0	0 - 0.0	-
Lymphoid leukaemia	26	1.3	1.6	1.0-2.2	599	NHL	56	3.7	2.7	1.9-3.6	460
Myeloid leukaemia	46	2.2	2.9	2.1-3.8	326	Melanoma (skin)	45	3.0	2.6	1.8-3.5	314
Leukaemia, other	0		0.0	0 - 0.0	-	Stomach	43	2.8	2.2	1.5-2.9	454
Bladder & urinary tract	76	3.7	4.3	3.3-5.3	298	Leukaemia	41	2.7	2.4	1.6-3.2	462
Oesophagus	73	3.6	4.9	3.7-6.0	159	Leukaemia NOS	1	0.1	0.0	0 - 0.1	*
Lymphoma	63	3.1	4.0	3.0-5.0	234	Lymphoid leukaemia	18	1.2	1.0	0.5-1.6	1191
Lymphoma NOS	4	0.2	0.2	0 - 0.3	*	Myeloid leukaemia	22	1.4	1.3	0.7-1.9	753
Hodgkin lymphoma	3	0.1	0.1	0 - 0.3	*	Leukaemia, other	0		0.0	0 - 0.0	-
NHL	56	2.7	3.7	2.7-4.7	234	Brain	38	2.5	2.7	1.7-3.6	330
Brain	60	2.9	4.3	3.2-5.4	191	Oesophagus	32	2.1	1.4	0.9-2.0	748
Mesothelioma	58	2.8	3.6	2.6-4.5	254	Uterus	31	2.0	1.9	1.2-2.6	427
Liver	50	2.4	3.2	2.3-4.1	282	Bladder & urinary tract	31	2.0	1.0	0.7-1.4	4017
Myelodysplastic diseases	43	2.1	2.5	1.7-3.2	486	Myelodysplastic diseases	31	2.0	1.6	0.9-2.2	651
Kidney	41	2.0	2.4	1.6-3.1	499	Cervix	27	1.8	1.5	0.9-2.2	640
Myeloma	39	1.9	2.3	1.5-3.0	441	Myeloma	23	1.5	1.0	0.6-1.5	1205
Skin (non-melanoma; includes)	38	1.9	2.2	1.5-2.9	519	Liver	22	1.4	1.2	0.6-1.7	756
Gallbladder / bile ducts	27	1.3	1.5	0.9-2.1	752	Gallbladder / bile ducts	19	1.2	0.8	0.4-1.3	1359
Lip, gum & mouth	18	0.9	1.2	0.6-1.8	704	Kidney	19	1.2	1.1	0.6-1.6	711
Pharynx	18	0.9	1.1	0.6-1.6	743	Mesothelioma	14	0.9	0.9	0.4-1.4	851
All cancers	2047	100.0	123.3	118-129	8	All cancers	1523	100.0	82.5	77.9-87.0	12